

UNIVERSITY OF MIAMI
Curriculum Vitae
Standard Format

(1) Date: February 24, 2014

I. PERSONAL

(2) Name: Lynn G. Feun (Sex : Male)

(3) Office Phone: (305)243-4978

(4) Current Academic Rank: Professor

(5) Primary Department: Medicine

(6) Secondary or Joint Appointment: None

(7) Citizenship: USA

(08) Visa Type (if non-citizen): N/A

II. HIGHER EDUCATION

(09) Institutional (institution; degree; date conferred):

1966 - 1970 Wayne State University, Detroit, MI , BA

1970 - 1974 Wayne State University, Detroit, MI , MD

Postgraduate training

July 1974 – June 1975 Internship, Harper Hospital, Wayne State University, Detroit, MI

July 1975 – June 1977 Residency, Harper Hospital, Wayne State University, Detroit, MI

July 1977 – June 1979 Fellow in Oncology, Harper Hospital, Wayne State University,
Detroit, MI

(10) Non-Institutional (description; dates): None

(11) Certification, licensure (description; board or agency; dates):

1977 American Board of Internal Medicine

1984 American Board of Oncology

State of Michigan: #040838
State of Texas: #F5906
State of Florida: #ME 0047736

III. EXPERIENCE

(12) Academic (institutions; rank/status; dates):

July 1979 - 1980	Faculty Associate and Instructor, Department of Developmental Therapeutics, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas.
July 1980 - 1983	Assistant Professor, Department of Developmental Therapeutics, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas.
July 1983 - 1985	Assistant Professor of Medicine, Department of Internal Medicine, Section of Neurology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas.
Sept. 1985	Associate Professor of Medicine, Department of Neuro-Oncology, University of Texas System Cancer Center, M.D. Anderson and Tumor Institute, Houston, Texas.
July 1985 – 1992	Associate Professor of Oncology, Department of Oncology, University of Miami School of Medicine, Miami, Florida.
1992-Present	Professor of Medicine - Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida.

(13) Hospital Appointments:

1985-present	Jackson Memorial Hospital, Attending Physician
1985-present	University of Miami Hospital and Clinics, Attending Physician

(14) Non-Academic (employers; title; responsibilities; dates): **None**

(15) Military (branch; rank; responsibilities; dates): **None**

IV. PUBLICATIONS:

Books and Book Chapters and Monographs:

Plunkett S, Nowak B, Feun LG, Benjamin RS, Keating M, and Freirich EJ: Modulation of Arabinosyladenine Metabolism of 2'-Deoxycoformycin in the Therapy of Human Acute Leukemia. *Purine Metabolism in Man-IV, Part B*. Plenum Publishing Corporation, p. 345-350, 1984.

Feun LG, Lee YY, Charnsangavej C, Yung WKA, Savaraj N, Carrasco CH, Gianturco C, and Wallace S: New Drugs and Delivery Techniques in Progress in Experimental Tumor Research. Vol 29:131-139 (Karger, Basel 1985).

Yung WKA, Hwang TL, Martinez J, Lee YY, Feun LG: Neurotoxicity of High Dose ARAC and Intracarotid Chemotherapy in Progress in Experimental Tumor Research. Vol 29:183-189 (Karger, Basel 1985).

Serafini AN, Kotler J, Feun L, Robinson D, Chattopadhyay K, Heal A, Dewanjee M, Ganz W, Sfakianakis G, Abrams P, and Nelp W. Specific Tc 99-m-labeled antimelanoma murine monoclonal antibody (NR-ML-057) Scintigraphy in patients with malignant melanoma (mm) in *Nuclear Medicine - Trends and Possibilities in Nuclear Medicine* Vol. 1:563-564 (Schattauer 1989).

Malignant Pleural Effusions: Recent advances in diagnosis and management. Monograph. Bristol-Myers Squibb Co. 1992

Landy HJ, Schwade JG, Houdek PV, Feun L, and Rodriguez M. Fractionated stereotactic radiation for glioma. In *Stereotactic Radiosurgery Update*. pp 421-424 (Elsevier Co 1992).

Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Winward KE, and Alexander KR. Cutaneous Melanoma-Associated Retinopathy.

Poochareon V, Savaraj N, Feun L. Chemotherapy for the treatment of skin cancer. In: *Skin Cancer*, McGraw-Hill 2008 pp 600-614

Feun L, Shonukan O, Li Ji. Targeted Therapy in Treatment of Melanoma. In: *Progress in Skin Cancer Research*, 2007 Nova Science Publishers, Inc.

Feun L, Kuo M-T, Wu C, Wangpaichitr and Savaraj N. Arginine Deiminase and Cancer Therapy In: *Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools*. John Wiley and Sons, Inc. Hoboken, NJ, 2010

Savaraj N, You M, Chunjing W, Kuo MT, Dinh V, Wangpaichitr M and Feun L. Targeting argininosuccinate synthetase in Cancer Therapy In: *Cell Signalling and Molecular Targets in Cancer*. Springer 2012 pp37-52

Sasine JP, Savaraj N, Feun LG. Inhibiting topoisomerase I, an emerging treatment for Primary CNS malignancies In: *Advances in Anti-Cancer Agents in Medicinal Chemistry*

(vol 1) 2013

(16) Juried or refereed journal articles and exhibitions:

Scientific Articles in Refereed Journals

1. Feun, LG, Drelichman A, Singhakowinta A, and Vaitkevicius VK: Ureteral Obstruction Secondary to Metastatic Breast Carcinoma. *Cancer* 44:1164-1171, 1979.
2. Feun LG, Drelichman A, Oishi N, Singhakowinta A, and Vaitkevicius VK: Phase II Study of Nafoxidine in the Therapy for Advanced Renal Carcinoma. *Cancer Treatment Report* 63:149-150, 1979.
3. Feun, LG, Samson MK, Stephens, RL: Vinblastine, Bleomycin, Cis-DDP in Disseminated Extragonadal Germ Cell Tumors: A Southwest Oncology Group Study. *Cancer* 45:2453-2549, 1980.
4. Feun, LG, Benjamin RS, Burgess MA, Gutterman J, McBride CM, Richman SP, Murphy WK, Hersh EM, Mavligit G, Bodey GP, Freireich EJ, Mountain CF, and Leavens ME: The Natural History of Resectable Metastatic Melanoma (Stage IVA Melanoma). *Cancer* 50:1656-1663, 1982.
5. Stewart, DJ, Leavens M, Maor M, Feun LG, Luna M, Bonura J, Loo TL, and Benjamin RS: Human Central Nervous System Distribution of Cis-Diamminedichloroplatinum and Use as a Radiosensitizer in Malignant Brain Tumors. *Cancer Research* 42:2474-2479, 1982.
6. Stewart DJ, Wallace S, Feun LG, Leavens M, Young SE, Handel S, Mavligit G, and Benjamin RS: Phase I Study of Intracarotid Artery Infusion of Cis-DDP in Patients with Recurrent Malignant Intracerebral Tumors. *Cancer Research* 42:2059-2062, 1982.
7. Stewart DJ, Benjamin RS, Luna M, Feun LG, Capriolo R, Seifert W, and Loo TL: Human Tissue Distribution of Platinum after Cis-DDP. *Cancer Research* 42:2474-2479, 1982.
8. Feun LG, Stewart DJ, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, and Bodey GP: A Phase II Trial of PCNU in Primary Malignant Brain Tumors of Neuro-Oncology. Vol. 1, No. 1, p. 45-48, 1983.
9. Savaraj N, Lu K, Feun LG, Leavens ME, Stewart DJ, Benjamin RS, and Loo TL: Intracerebral Penetration and Tissue Distribution of AZQ. *J. of Neuro-Oncology* Vol. 1, No. 1, p. 15-19, 1983.
10. Stewart DJ, Feun LG, Maor M, Leavens M, Burgess MA, Benjamin RS, and Bodey GP: Weekly Cisplatin During Cranial Irradiation for Malignant Melanoma Metastatic in Brain. *J. of Neuro-Oncology*, Vol. 1, No. 1, p. 49-51, 1983.

11. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WA, and Benjamin RS: A Pilot Study of Cis-DDP and Radiation Therapy in High grade Astrocytomas. *J. of Neuro-Oncology* 1:109-113, 1983.
12. Feun LG, Savaraj N, Lu K, Guo Z, Raulston LG, Benjamin RS, and Loo TL: The Pharmacologic Fate of 2,5-Diaziridinyl-3,6-BIS(Carboethoxyamino) 1,4-Benzoquinone (AZQNSC-182986) by Intracarotid or Intravenous Administration in Beagles. *J. of Neuro-Oncology* 1:219-224, 1983.
13. Lu K, Savaraj N, Yap BS, Bedikian AY, Feun LG, and Loo TL: Clinical Pharmacology of 2,5-Diaziridinyl-3,6-BIS(Carboethoxyamino) 1,4-Benzoquinone (AZQ). *Euro. J. Cancer and Clin. Oncol.* 19:603-606, 1983.
14. Guo ZG, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, and Loo TL: Tumor Penetration of AMSA in Man. *Cancer Investigation* 1 (6):475- 478, 1983.
15. Feun LG, Yung WKA, Leavens ME, Burgess MA, Obbens E, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, and Bodey GP: A Phase II Trial of 1,5-Diaziridinyl 3,6-BIS (Carboethoxyamino) 1,4, Benzoquinone (AZQ, NSC 182986) in Recurrent Primary Brain Tumors. *J. Neuro-Oncology* 2:13-17, 1984.
16. Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin RS, Keating MJ, and Loo TL: Human Tissue Distribution of 4'-(9-acridinylamino) -methanesulfon-m- anisidide (NSC141549, AMSA). *Cancer Chemother. Pharmacol.* 12:116-119, 1984.
17. Plunkett W, Feun LG, Benjamin RS, Keating M, Freireich EJ: Modulation of Vidarabine Metabolism by 2'- Deoxycoformycin for Therapy of Acute Leukemia. *Cancer Treatment Symposia* 2:23-27, 1984.
18. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, and Krakoff I: Phase I Study of Tricyclic Nucleoside Phosphate Using a 5 day Continuous Infusion Schedule. *Cancer Research* 44:3608-3612, 1984.
19. Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid Infusion of Cis-diamminedichloroplatinum in the Treatment of Recurrent Malignant Brain Tumors. *Cancer* 54:794-799, 1984.
20. Feun LG, Wallace S, Yung WKA, Lee YY, Leavens ME, Moser R, Savaraj N, Burgess MA, Plager C, Benjamin RS, Tang RA, Mavligit GM, and Fields S: Phase I Trial of Intracarotid BCNU and Cisplatin in Patients with Malignant Intracerebral Tumors. *Cancer Drug Delivery* 1:239-245, 1984.

21. Feun LG, Savaraj N, and Ozarda AT: Cisplatin in Medulloblastoma with Extracranial Metastasis: A Case Report. *Cancer Treatment Reports* 68:1307-1309, 1984.
22. Feun LG, Yung WKA, Stewart DJ: Phase II Trial of Methyl-GAG (MGBG) in Malignant Primary Brain Tumors. *Cancer Treat. Reports* 69:329-330, 1985.
23. Obbens E, Feun LG, Leavens ME, Savaraj N, Stewart DJ, and Gutterman JU: Phase I Clinical Trial of Intralesional or Intraventricular Leukocyte Interferon for Intracranial Malignancies. *J. of Neuro-Oncology* 3:61-67, 1985.
24. Charnsangavej C, Lee YY, Carrasco CH, Feun LG, Tang RA, Wright K, Wallace S, and Gianturco C: Supraclinoid Intracarotid Chemotherapy Using a Flow-Directed Soft-tipped Catheter. *Radiology* 155:655-657, 1985.
25. Feldman LD, Feun LG, Benjamin RS, Yap BS, Plager C, Papadopoulos N, Savaraj N, Burgess MA, and Bodey GP: A Phase II Trial of PCNU in Patients with Malignant Melanoma and Central Nervous System Metastases. *Am. J. of Clin. Oncology* 8:215-217, 1985.
26. Feun LG, Lee YY, Yung W-KA, Charnsangavej C, Savaraj N, Tang RA, and Wallace S: Phase II Trial of Intracarotid BCNU and Cisplatin in Primary Malignant Brain Tumor. *Cancer Drug Delivery* 3:147-156, 1986.
27. Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, and Loo TL: Clinical Pharmacology of 4-demethoxydaunorubicin DMDR. *Can. Chemo. Pharm.* 17:143-148, 1986.
28. Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, and Loo TL: Clinical Pharmacology of Intracarotid Etoposide. *Cancer Chemotherapy and Pharmacology* 16:292-294, 1986.
29. Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, and Loo TL: Clinical Pharmacology of Homoharringtonine. *Can. Treat. Rep.* 70:1403-1407, 1986.
30. Lu K, Savaraj N, Yap BS, Feun LG, Umsawadi T, and Loo TL: Clinical Pharmacokinetics of 9,10-anthracenedicarboxaldehyde-bis-[4,5 dihydro-1H-imidazol-2yl)Hydrazone] Dihydrochloride. *Can. Chemo. Pharm.* 16:156-159, 1986.
31. Feun LG, Lee YY, Yung W-KA, Savaraj N, and Wallace S: Intracarotid VP-16 in Malignant Brain Tumors. *J. Neuro-Oncology* 4:397-401, 1987.
32. Wright KC, Stephens LC, Wallace S, Savaraj N, Feun LG. Experimental Combination Chemotherapy: Intracarotid Versus Intravenous Administration of Aziridinybenzoquinone, BCNU, and Cisplatin in Dogs. *Chemotherapy* 33 (6) 437-44, 1987.
33. Savaraj N, Lu K, Feun LG, Burgess MA and Loo TL: Comparison of CNS Penetration, Tissue Distribution and Pharmacology of VP-16 213 by Intracarotid and Intravenous Administration in Dogs. *Cancer Investigation* 5:11-16, 1987.

34. Savaraj N, Feun LG, Lu K, Leavens M, Moser R, Fields WS, and Loo TL: Central Nervous System (CNS) Penetration of Homoharringtonine(HHT). *J. Neuro-Oncology* 5:77-81, 1987.
35. Feun LG, Savaraj N, Legha S, Silva EG, Benjamin RS and Burgess MA:Chemotherapy for Metastatic Merkel Cell Carcinoma. *Cancer*, 62:683-685, 1988.
36. Lu K,Savaraj N, Feun LG, Zhengang G, Umsawadi T, and Loo TL. Pharmacokinetics of homoharringtonine in Dogs. *Cancer Chemother. Pharmacol.* 21:139-142, 1988.
37. Sridhar KS, Hussein AM, Feun LG, Zubrod CG. Activity of Pirarubicin(4'-O'-Tetrahydropyranyladriamycin)in Malignant Mesothelioma. *Cancer* 63: 1084-1091, 1989.
38. Savaraj N, Lian J, Lu K, Feun L, and Hsu TC: Gentotoxicity of IH-Benz[DE] Isoguinoline-1, 3(2H)-Dione 5Amino-2-, [2-Dimethylamino](Ethyl)BIDA in Human Lymphocytes. *Cancer Investigation.* 7 (2) 117-121, 1989.
39. Hussein AM, Savaraj N, Feun LG, Ganjei P, and Donnelly E.Carcinomatous Meningitis from transitional cell carcinoma of the bladder: Case Report *J Neuro-Onc.* 7:255-260, 1989.
40. Yung WKA, Harris MI, Bruner JM and Feun LG. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. *J Neuro-Onc* 7:237-240, 1989.
41. Smith RG, Cheung LK, Feun LG, and Loo TL:Determination of 1-(2-Chloroethyl)-3-(2,6-dioxo-3-peiperidyl)-1-nitrosurea in Plasma by Negative Chemical Ionization Mass Spectrometry. *Bio. Medical Mass Spectrometry.* 7:404-7,1983.
42. Serafini AN, Kotler J, Feun L, Dewanjee M, Savaraj N, Robinson D, Sfakianakis, Abrams P, Goodwin D, and Nelp W. Technetium-99m Labeled Monoclonal Antibodies in the Detection of Metastatic Melanoma. *Clinical Nuclear Medicine* August 1989.
43. Hussein AM and Feun LG. Tumor lysis syndrome after induction chemotherapy in small cell lung carcinoma. *American Journal of Clinical Oncology.* 13(1):10-13,1990.
44. Hussein AM, Feun LG, Sridhar K, Otrakji CL, Moore MG, Benedetto P. Small cell carcinoma of the Large Intestine Presenting as Central Nervous System Signs and Symptoms. *J. Neuro-Onc.*8:269-274, 1990.
45. Hussein AM, Feun LG, Albores, and East D: Carcinoid tumor presenting as central nervous system symptoms: Case Report and Review of the Literature. *Am J Clin Oncol* 13:251-255, 1990.
46. Sridhar. KS, Samy TSA, Koch, G, Agarwal, RP, Duncan RC, Ganz WI, Benedetto, P, Feun, LG, Savaraj, N, Gross, J, Krishan, A and Zubrod CG.Phase I study of 4'0'-Tetra

hydropyranyl adriamycin Cancer. *Advances in Experimental and Clinical Chemotherapy*. 15th International Congress of Chemotherapy p.11-26, 1988.

47. Feun LG, Maor M, Stewart DJ, Leavens ME, Yung WK, Savaraj N, Burgess, MA, Benjamin RS, Fields WS, and Bodey GP. A Pilot Study of PCNU and Cranial Radiation Therapy in the Treatment of Patients with Malignant Gliomas. *Oncology* 47:389-392, 1990.
48. Feun LG, Savaraj N, Landy H, Levin H and Lampidis T. Phase II Study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. *J. Neuro-Oncol* 9:159-163, 1990.
49. Feun LG, Lee YY, Plager C, Papadopoulos N, Savaraj N, Charnsangavej C, Benjamin RS and Wallace S. Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases. *Am J Clin Oncol*.13:448-451,1990.
50. Feun LG, Savaraj N. Detection of occult bone metastases by magnetic resonance imaging. *J Fl Med Assoc* 77:881-883, 1990.
51. Serafini AN, Vargas-Cuba R, Benedetto P, Legaspi A, Feun L, Robinson D, Ardalan B, Dewanjee MK, Sevin BU, Averette H, and Sfakianakis G. Clinical experience in utilizing radiolabeled monoclonal antibodies. *Antibody, Immunoconjugates and radiopharmaceuticals* 4:77-83, 1990.
52. Sridhar KS, Samy TS, Agarwal RP, Duncan RC, Benedetto P, Krishan AG, Vogel CL, Feun LG, Savaraj N, Richman SP and Zubrod CG. Phase I study of Pirarubicin (4'0 - Tetrahydropyranyladriamycin): Clinical pharmacology and pharmacokinetics. *Cancer* 66:2082-2091, 1990.
53. Levy I and Feun LG: Hypercalcemia and malignant melanoma. *Am J Clin Oncol* 13:524-526, 1990.
54. Hussein AM, Feun LG, Sridhar KS, Benedetto P, Waldman S, and Otrakji C. Combination chemotherapy and radiotherapy for small cell carcinoma of the esophagus: A Case Report of Long Term Survival and Review of the Literature. *Am J Clin Oncol* 13:369, 1990.
55. Feun LG, Albores S, Savaraj N. Osteosarcoma arising adjacent to a longstanding ameloblastoma, Oral surgery, Oral medicine and Oral pathology 71-79, 1991.
56. Feun LG, Savaraj N, Benedetto P, Sridhar K, Hanlon J, Collier M, Richman S, and Clendennin NJ. Phase I Trial of Piritrexim (BW 301, PTX) Capsules Using Prolonged Low-Dose Administration. *J Natl Can Inst* 83:51-55, 1991.

57. Feun LG, Gonzales R, Savaraj N, Hanlon J, Collier M, Robinson WA and Clendeninn NJ. Phase II trial of piritrexim(301u, 74, PTX) capsules in metastatic melanoma using prolonged, low-dose administration. *J Clin Oncol* 9:464-467, 1991.
58. Von Hoff DD, Fleming T, McDonald JS, Goodman PJ, Damme JV, Brown TD, O'Rourke TD, Feun LG and Keppen MD. Phase II trial of gamma-interferon in pancreatic cancer. *J Biol Res Med* 9:584-587, 1990.
59. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A. A Phase II study of weekly 24-hour infusion with high dose 5-Fluorouracil (5FU) with leucovorin(LV) in colorectal carcinoma. *J Clin Oncol* 9:625-630, 1991.
60. Feun LG, Savaraj N, Lee YY, Landy H, Martinez-Prieto J, Charnsangavej C, Post JD, Lee KF, Wallace S, Bowen B, Kochan JP and Yung WKA. A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin. *Selective Cancer Therapeutics* 7:29-36, 1991.
61. Whitehead RF, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, Hersh EM and Rinehart JJ. A Phase II study of IV Bolus Recombinant Interleukin-2 in Advanced Malignant melanoma: A Southwest Oncology Group Study. *J Natl Can Inst* 83:1250-1252, 1991.
62. Ardalan B, Sridhar S, Rajender R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N and Livingstone A. Phase I study of high dose 5-Fluorouracil and high dose Leucovorin with low dose PALA in patients with advanced malignancies. *International Journal of Radiation Oncology, Biology, Physics* 22:511-514, 1992.
63. Feun LG, Savaraj N, Bujnoski J and Nadeem S. Spinal cord compression produced by osteomyelitis mimicking spinal epidural metastasis, *Am J Clin Oncol* 15(2):174-179, 1992.
64. Nadeem SQ, Feun LG, Bruce-Gregorios JH, and Green B. Post radiation sarcoma (Malignant Fibrous Histiocytoma) of the cervical spine following ependymoma (A Case Report) *J of Neuro-Oncology* 11:263-268, 1991.
65. Ardalan B, Sridhar K, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, and Livingstone A. Phase I and II study of high-dose 5-Fluorouracil and high dose Leucovorin with low dose PALA in patients with advanced malignancies *Cancer* 68:1242-1246, 1991.
66. Sridhar KS, Hussein AM, Benedetto P, Waldman S, Feun L, Savaraj N, and Richman SP. Phase II trial of Mitoxantrone in head and neck carcinoma. *Am J Clin Oncol* 14 (4):298-304, 1991.

67. Moore MLG, Savaraj N, Feun LG and Donnelly E. Successful therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone: A Case Report. *Am J Clin Oncol* 15:528-530, 1992.
68. Savaraj N, Feun LG, Luk, Gray K, Wang C and Loo TL. Pharmacology of intrathecal VP16-213 in Dogs. *J Neuro-Oncology. J Neuro-Onc* 13:211-215. 1992.
69. Yung WKA, James T.J., Maor M, and Feun LG. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. *J Neuro-Onc* 12:131-136, 1992.
70. Raub WA, Jr, Feun LG, Duncan RC. Descriptive analysis of the tumor registry experience for malignant melanoma from 1977-1986 at the Jackson Memorial Hospital(JMH), University of Miami School of Medicine CRC Cancer Detection and Prevention 16:193-202, 1992.
71. Savaraj N, Wu CT, Lampidis TJ, Chua LK and Feun LG. In-vitro cytotoxicity of U-73975 in multidrug and cisplatin resistant cells. *Cellular Pharmacology* 3:1-4, 1994.
72. Milam AH, Sarri JC, Jacobson SG, Lubinski WP and Feun LG. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. *Invest Ophthalmol Vis Sci* 34 (1) 91-100, 1993. *Investigative Ophthalmology and Visual. Science* 34:91-100, 1993.
73. Feun LG, Blessing JA, Barrett RJ, and Hanjani P. A Phase II trial of tricyclic nucleoside phosphate (TCN-P) in patients with advanced squamous cell carcinoma of the cervix - A Gynecologic Oncology Group study *Am J Clin Oncol*, (6) 506-508, 1993.
74. Feun LG, Blyden G, Yrizarry J, Dorvil M, Waldman S, Benedetto P, Donnelly E, Curtas J, George M, and Savaraj N. Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa (*Cancer Biotherapy*, 8:43 - 48 1993).
75. Wolfson AH, Snodgrass SM, Schwade JG, Markoe AM, Landy H, Feun L, Sridhar K, Brandon AH, Rodriguez M, and Houdek P. The role of steroids in the management of metastatic carcinoma of the brain: A pilot prospective trial, (*Am J Clin Oncol*, 17 (3) 234-238, 1994.
76. Landy HJ, Feun L, Schwade JG, Snodgrass S, Wu Y, and Gutman F. Retreatment of Intracranial Gliomas (*Southern Medical Journal*). 87:211-214, 1994.
77. Savaraj N, Feun LG, Blyden G. Yrizarry JM, Hsiang RT, Curtas J, Waldman S, Post J, Benedetto P, Landy H and Garcia JJ. A pilot clinical and pharmacological study of intra-arterial infusion of thiotepa. *Cancer Biotherapy* 8:37-42, 1993.
78. Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ, Purser RK, Waldman S, Levi JU, Moffat F, Morrell L, Livingstone AS, Ardalán B and Benedetto P. A phase I study of

chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. *Am J Clin Oncol* 17:405-410, 1994.

79. Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, Livingstone AS, Ardalan B, Levi JU, Parker T, and Schiff ER. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. *Am J Clin Oncol* 17:393-395, 1994.
80. Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, and Clendennin NJ. Oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy? *Am J Clin Oncol*, 17 (5): 448-451, 1994.
81. Borruat FX, Schatz NJ, Feun L, Matos L, Glaser JS. Visual recovery from radiation induced optic neuropathy. The role of hyperbaric oxygen therapy. *J Clin Neuroophthalmol* 13:98-101, 1993.
82. Hsu TC, Feun L, Trizna Z, Savaraj N, Shirley L, Furlong CL, Schantz SP, Weber RS, Shen T-J, and Kueuk O. Differentiated sensitivity among three human subpopulations in response to 4-nitroquinoline-1-oxide and to bleomycin. *International J of Oncol* 3:827-30, 1993.
83. Hsu LC, Savaraj N, Trizna Z, Feun L, Furlong CL, Schantz SP, and Shirley L. Cytogenetic studies on the in vitro genotoxicity of 4-nitroquinoline-1-oxide on human lymphocytes. *International J of Oncol* 3:823-26, 1993.
84. Feun LG, Raub WA, Jr., Duncan RC, Moffat F, Savaraj N, Nemeth A, Markoe A and Trapido E. Melanoma in a Southeastern Hispanic Population. *Cancer Detection and Prevention* 18 (2):145-152, 1994.
85. Serafini AN, Vargas-Cuba R, Jacobs W, Kotler J, Feun L, Artze M, Dewwanjee M, Sfakianakis GN, Savaraj N, Robinson D. A review of the status of immunoscintigraphy in patients with malignant melanoma. *Diagnostic Oncology* 3 (4) 183-188, 1994.
86. Feun LG, Savaraj N and Landy JH. Drug resistance in brain tumors. *J Neuro-Oncol* 20:165-176, 1994.
87. Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K and Clendennin NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma *Am J Clin Oncol* 18:488-490, 1995.
88. Meyskens Jr., FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. A randomized trial of human interferon α versus observation for the adjuvant treatment of high-risk malignant melanoma: A Southeast Oncology Group Study *J Nat Can Inst* 87:1710-1713, 1995.

89. Landy H, Schwade JG, Houdek PV, Markoe AM, and Feun L. Long term follow-up of gliomas treated with fractionated stereotactic irradiation ACTA, *Neurochir* 62:26-30, 1994.
90. Feun LG, Savaraj N, Solomon J, Liebman A, and Hurley J. Phase II trial of mitoxantrone and cisplatin in advanced, non-small cell lung cancer. *Am J Clin Oncol* 19:190-192, 1996.
91. Snodgrass SM, Landy H, Markoe AM, Feun L. Neurologic complications of merkel cell carcinoma. *J Neuro-Onc* 22:231-234, 1994.
92. Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J, Raub, Jr., W. and Richman S. Phase II trial of recombinant alpha-interferon (Intron) with BCNU, Cisplatin, DTIC, and Tamoxifen in advanced, malignant melanoma. *Melanoma Research*, 5:273-276, 1995.
93. Feun LG, Raub Jr, W, Landy H, Green B, Wolfson A, Markoe A. Retrospective epidemiologic analysis of patients diagnosed with intracranial meningiomas from 1981 to 1990 at Jackson Memorial Hospital, Sylvester Comprehensive Cancer Center: The Jackson Memorial Tumor Registry Experience. *Cancer Detection and Prevention* 20:166-170, 1996.
94. Savaraj N, Wu CJ, Xu R, Feun LG, Lampidis TJ, Tapiero N, and Kuo MT. Quantitative Multi-Drug Resistance Associated Protein (MRP) Gene Expression by Competitive Reverse - Transcription Polymerase Chain Reaction (RT-PCR). *Cellular Pharmacology*.
95. Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG. Multidrug-resistant Gene Expression in Small-Cell Lung Cancer. *Am J Clin Oncol* 20:398-403, 1997.
96. Khorsand M, Lange J, Feun L, Clendennin N, Collier M, Wilding G. Phase II trial of oral piritrexim in advanced previously treated transitional cell cancer of bladder. *Invest. New Drugs* 15 (2): 157-63, 1997.
97. Abdel-Wahab MM, Wolfson AN, Raub W, Landy H, Feun L, Sridhar K, Brandon AH, Mahmood S, Markoe AM. The role of hyperfractionated irradiation in metastatic brain disease: A single institutional trial. *Am J Clin Oncol*. 20 (2) 158-60, 1997.
98. Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, and Berck JS. A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study, *Gynecology Oncology* 71:410-415, 1998.
99. Feun, LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schwartz M, Savaraj N, Livingstone AS, Levi JN, Jeffers LJ, Ardalan B, Schiff ER. A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. *American J of Clin Oncol* 22:375-380, 1999.

100. Raez LE, Patel P, Feun L, Restrepo, Raub, Jr. WA, and Cassileth PA. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma. *Critical Rev Oncogene* 9:199-208, 1998.
101. Feun LG, Savaraj N, Hurley J, Marini A, and Lai S. A clinical trial of intravenous Navelbine plus Tamoxifen in Advanced Malignant Melanoma. *Cancer* 88:584-588, 2000.
102. Zou J, Landy H, Feun L, Xu R, Lampidis T, Wu CJ, Furst AJ, Savaraj N. A unique 220-kd protein correlates with vitamin D sensitivity in glioma cells. *Biochem Pharmacology* 60:1361-1365, 2000.
103. Landy HJ, Lee TT, Potter P, Feun L, Markoe A. Early MRI findings in high grade glioma. *J Neuro-Onc* 47:65-72, 2000.
104. Savaraj N, Wu CT, Wangpaichitr M, Kuo M, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated multidrug resistance associated protein MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity azidothymidine. *International J of Oncology* 23:173-179, 2003
105. Feun LG, Savaraj N, Hurley J, and Marini A. Phase II Trial of Paclitaxel and acarbazine with Filgrastim administration in advanced malignant melanoma. *Cancer Invest.* 20 (3) 1-5, 2002.
106. Agarwal S, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman G, Gonzalez, Hersh G, Feun L, Belt D, Meyskens F, Hellstrand K, Wood D, Kirkwood J, Nhlson K, Naredi P. Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 vs interleukin-2 alone in patients with metastatic melanoma: *JCO* 20:125-133, 2002.
107. Feun, L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Golacine E, Fischer J, MacDonald S. Phase I and pharmacokinetic study of 3-aminopyridine-2 carboxyaldehyde Thiosemicarbaz using a single intravenous dose schedule (*Cancer Chemotherapy and Pharmacology* 50:223-9, 2002).
108. Feun LG, O'Brien C, Molina G, Rodriguez M, Jeffers L, Schiff E, Marini A, Savaraj N, Ardalan B. Phase II Trial of Recombinant Leukocyte Interferon, Doxorubicin, and 5-FUDr in Patients with Hepatocellular Carcinoma. *Cancer Research and Clinical Oncology* 129:17-20, 2003
109. Robles C, Furst AJ, Sriratana P, Lai P, Chua L, Donnelly E, Solomon J, Sundaram M, Feun L, Savaraj N. Phase II study of vinorelbine with low dose prednisone in treatment of hormone refractory prostate cancer. *Oncol Rep* 10(4):885-9, 2003.

110. Prados MD, Schold SC, Fine H, Jaeckle K, Hochberg F, Mechtler L, Fetell M, Phuphanich S, Feun L, Janus T, Downing G, Ford K, Graney W. A randomized, double-blind, placebo-controlled, phase II study of RMP-7 in combination with caboplatin administered intravenously for the treatment of recurrent malignant glioma. *Neuro-oncology* 5: 96-103, 2003.
111. Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Reis I, Heros D, Wangpaichitr, and Feun L. Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade gliomas. *J of Neuro-oncology. J Neuro-Oncol* 67 (1-2):215-20, 2004.
112. Wei Y, Lin-Lee Y-C, Zhao, S, Rassool FV, Shin AA, Meistrich ML, Wang R-A, Kumar R, Elgart GW, Feun L, and Kuo MT. Molecular cloning of the CHO chromosomal fragile site DNA implicated in multidrug resistance gene amplification reveals a novel gene whose expression is associated with epithelial differentiation (In press).
113. Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, Savaraj N. Procollagen-like Protein as a molecular target in the treatment of primary brain tumor. *Scientific World Journal* 2;2 (1 Suppl 2): 125-6, 2002.
114. Landy H, Feun L, Markoe A, Patchen S, Bruce J, Marcus J, Levi A. Extended remission of recurrent median nerve malignant peripheral nerve sheath tumor after multimodality treatment. *J Neurosurg* 103: 760-763, 2005.
115. Feun L, Marini A, Moffat F, Savaraj N, Hurley J, and Mazumder A. Cyclosporine A, alpha interferon, and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: A phase II study. (*Cancer Invest*, 23: 3-8, 2005).
116. Ascierto P, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, DeRosa V, Izzo F, Ensor C, Holtsberg F, Bomalaski J, Clark M, Curley S, Savaraj N, Feun LG, and Logan T. Pegylated arginine deiminase treatment of subjects with metastatic melanoma: results from Phase I and II studies. *JCO* 23: 7660-7668, 2005.
117. Savaraj N, Wu, C, Landy H, Medhi W, Wei Y, Kuo MT, Robles C, Furst AJ, Lampidis, T, and Feun, L. Procollagen alpha 1 type 1: A potential aide in histopathological grading and a marker for vitamin D sensitivity in primary brain tumor. *Cancer Invest* 23:577-581, 2005
118. Wei Y, Lin-Lee Y-C, Yang X, Zhao S, Rassool FV, Elgart G, Feun LG, Savaraj N and Kuo MT. The characterization of the CHO 1q31 chromosomal fragile site and its implication in the controls of multidrug resistance gene amplication and epithelial differentiation and tumor development. (submitted)

119. Wu C-J, Wangpaichitr M, Feun LG, Kuo MT, Robles C, Lampidis T, and Savaraj
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. *Molecular Cancer*
4:25, 2005.
120. Wei Y, Lin-Lee Y, Yang X, Dai W, Zhao S, Rassool FV, Elgart G, Feun L, Savaraj N,
and Kuo TM. Molecular Cloning of Chinese Hamster 1q31 Chromosomal Fragile Site
DNA that is important to mdr1 Gene Amplification Reveals a Novel Gene Whose
Expression is Associated with Spermatocyte and Adipocyte Differentiation. *Gene*
372:44-52, 2006.
121. Feun LG, Marini A, Landy H, Markoe A, Heros D, Robles C, Herrera C, and Savaraj
N. Clinical trial of CPT-11 and VM26/VP16 for patients with recurrent malignant brain
tumors. 2006, *Journal of Neuro-Oncology*
122. Feun L, Savaraj N. Pegylated Arginine Deiminase: A Novel Anticancer Enzyme
Agent. *Expert Opinion on Investigational Drugs* Jul;15 (7):815-22.2006
123. Dinh V, Feun L, Elgart G, Savaraj N. Merkel cell. *Hematology/Oncology Clinics of
North America* 21: 527-544, 2007
- 124 Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton
J, Gallo J, and Kennealey. A Phase III randomized controlled trial comparing the survival
of patients with unresectable hepatocellular carcinoma treated with nolatrexed or
doxorubicin. *J of Clinical Oncology* 25:3069-3075, 2007
124. Cebulla CM, Alegret A, Feun L, Markoe A, Murray T. Ocular manifestations of
aggressive metastatic melanoma. (*Retinal Cases & Brief Reports*, 2007)
125. Savaraj N, Wu c. Kuo M-T, You M, Wangpaichitr M, Robles C, and Feun L. The
relationship of arginine deprivation, argininosuccinate synthetase and cell death in
melanoma. (*Drug Target Insights*, in press)
126. Feun L, You M, Wu C-J, Kuo MT, Wangpaichitr M, Spector S and Savaraj N.
Arginine deprivation as a targeted therapy for Cancer (*Current Pharmaceutical Design*
14(11):1049-57, 2008
127. Savaraj N, You M, Wu C-J, Kuo MT, Wangpaichitr M, Spector S, and Feun L.
Modulation of argininosuccinate synthetase expression by arginine deprivation involving
mTOR signaling in melanoma. (submitted).

128. Feun L and Savaraj N. Topoisomerase I inhibitors for the Treatment of Brain Tumors. *Expert Review of Anticancer Therapy* 8(5): 707-716, 2008.
129. Aiba I, Lee S-Y, Feun L, Savaraj N, and Kuo M.T. Induction of Argininosuccinate Synthetase by arginine depletion dependent activation of PI3K/Akt/c-Myc pathway confers ADI resistance in melanoma (submitted).
130. Wangpaichitr M, Wu C, You M, KUO MT, Feun L, Lampidis T, Savaraj N. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. *European Journal of Pharmacology* 591:124-127, 2008.
131. Aiba I, Tsai W-B, Lee S-Y, Feun L, Savaraj N, Kuo M-T. Induction of Argininosuccinate synthetase expression by arginine depletion involves interplays of c-Myc/HIF1 α /Sp4 that confers arginine deiminase- resistance in melanoma (submitted)
132. Wu J, Henderson C., Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Chen H-B, Rosenzweig B, Hochster H, Muggia F, Abbadessa G, Lewis J, and Zhu AX. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma *Investigational New Drugs* 2009
133. Tsai W-B, Aiba I, Lee S-Y, Feun L, Savaraj N and Kuo MT. Resistance to Arginine Deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving the interplays of c-Myc/HIF-1 α /Sp4 transcription regulators. *Molecular Cancer Therapeutics* 2009: 3223-33
- 134 Wangpaichitr M, Wu C, You M, Maher JC, Dinh, Vy Feun L and Savaraj N *N¹,N³-Dimethyl-N¹,N³-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)* *Cancers* 2009 (1): 23-28
135. You M, Savaraj N, Wangpaichitr M, Wu C-J, Kuo MT, Varona-Santos J, Nguyen D and Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. *Biochemical and Biophy Res Comm* 394(3) 2010:760-766
136. Levi D, Tzakis A, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo B, Narayanan G, Garcia M, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone A. Liver Transplantation for Hepatocellular Carcinoma in the MELD era. (*J Am Coll Surg* 210: 727-736, 2010).
137. Savaraj N, You M, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, Autophagy, apoptosis (AAA) for the treatment of melanoma. *Curr Mol Med* June 10 (4): 405-12, 2010

- 138 Kuo MT, Savaraj N, and Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. *OncoTarget* 1 (4) 246-251, 2010
- 139 Wykoff, C. Murray T, Markoe A, Feun LG, Scheffler AC, Gayer S
Preoperative evaluation for patients with choroidal/ciliary body melanomas: what is necessary? *American Journal of Ophthalmology* June, vol 151: 921-924, 2011
140. Saskine J, Savaraj N, Feun LG: Topoisomerase I inhibitors in Malignant Brain Tumors
Anti-cancer drugs in Medicinal Chemistry 10:683-696, 2010.
- 141 You M, Savaraj N, Kuo MT, Wangpaichitr M,
Wu C and Feun L TRAIL Attenuates Autophagy in Melanoma Cells under Arginine Deprivation through Caspase Activation. *International J of Cancer* 2012
- 142 . Steven Eric Finkelstein, Andy Trotti, Nikhil Rao, Douglas Reintgen, Wayne Cruse, Lynn Feun, Vernon K. Sondak, Weiwei Zhu, Daohai Yu, Clement Gwede and Ronald DeConti The Florida Melanoma Trial I: A prospective multi-center phase I/II trial of post operative hypofractionated adjuvant radiotherapy with concurrent interferon-alfa-2b immunotherapy in the treatment of advanced stage III melanoma with long term toxicity follow up *ISRN Immunology* 2012
143. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalski J, Savaraj N
Negative argininosuccinate synthetase (ASS) expression in melanoma tissue may predict clinical benefit from arginine depleting therapy with pegylated arginine deiminase. Apr 24, 2012 – **Br J Cancer** 106: 1467-1468;
144. Tsai W-B, Aiba I, Long Y, Lin H-K, Feun L, Savaraj N, Kuo MT
Activation of Ras/PI3K/ERK pathway induces c-myc stabilization to upregulate Argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells (*Cancer Research* May 15, 2012 72: 2622-33)
145. Kim J-K, Frankel AE, Georgiou G, Feun L, Ekmekeioglu S, Kim K.
Arginine-deprivation therapy for malignant melanoma (*Clinical Pharmacology: Advances and Applications* 2013:5 11-19.
146. You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu CJ, Nguyen DM, Feun L. Trail induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. *Mol Cell Biochem* (in press)
147. Tsai W-B, Long Y, Aiba I, Savaraj N Feun LG, and MT Kuo
Arginine deprivation induces translational shock of HIF1 α synthesis to de-repress argininosuccinate synthetase 1 expression, leading to arginine deiminase resistance

in melanoma cells (submitted)

- 148 Long, Y, Tsai W-B, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo M-T
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence and glutamine addiction
Mol Cancer Ther November 2013 12:2581-2590

(17) Other works and publications:

Multicenter Collaborative Studies

1. Technetium-Labeled Monoclonal Antibodies For Imaging Metastatic Melanoma: Results of a Multicenter Clinical Study. *Seminars in Oncology* Vol 15:608-618, 1988.
2. Intrapleural Therapy for Malignant Pleural Effusions: A randomized comparison of bleomycin and tetracycline.
3. The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled *ARCH Ophthalm* 119: 951-965, July 2001.
4. The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma, III. Initial Mortality Findings. *ARCH Ophthalm* 119: 969-982, July 2001.

Abstracts

1. Feun LG, Samson M: Vinblastine, Bleomycin, and Cis-DDP II in Disseminated Extragonadal Germ Cell tumors. *Amer. Soc. of Clinical Oncology* 20:369, 1979.
2. Benjamin RS, Plunkett W, Ketting MJ, Feun LG, Hug V, Nelson JA, Bodey GP, and Freireich EJ: Phase I and Biochemical Pharmacological Studies of Deoxycoformycin. *Amer. Soc. of Clinical Oncology* 21:337, 1980.
3. Feun LG, Burgess AM, Gutterman J, Mavligit G, McBride CM, Hersh EM, Benjamin RS, Gehan EA, Murphy WK: The Natural History of Stage IVA Melanoma. *Amer. Soc. of Clinical Oncology* 22:427, 1981
4. Feun LG, Stewart DJ, Leavens ME, Benjamin RS, Bodey GP: Phase II Study of PCNU in Recurrent Malignant Brain Tumors. *Amer. Assoc. of Cancer Research* 22:267, 1981
5. Stewart DJ, Wallace S, Leavens M, Young S, Feun LG, Mavligit G, Benjamin RS, and Freireich EJ: Phase I study of Intracarotid Cis-DDP in Patients with Intracerebral Tumors. *Amer. Assoc. of Cancer Research* 22:189, 1981.

6. Plunkett W, Benjamin RS, Feun, LG, Keating M, and Freireich EJ: Cellular Concentrations of dATP and ara-ATP in Peripheral Blood Leukemic Cells and Erythrocytes from Patients Treated with DCF or Arabinosyladenine. *Amer. Assoc. of Cancer Research* 22:177, 1981.
7. Savaraj N, Lu K, Stewart DJ, Leavens M, Benjamin RS, Bedikian A, Feun LG and Loo TL: Tissue Distribution and Intracerebral Tumor Penetration of AZQ in Man. *Amer. Soc. of Clinical Oncology* 22:351, 1981
8. Lu K, Savaraj N, Yap BS, Benjamin RS, Bedikian AY, Feun, LG, and Loo TL: Clinical pharmacology of AZQ. *Amer. Assoc. of Cancer Research* 22: 180, 1981.
9. Feun LG, Wallace S, Stewart DJ, Leavens M, Savaraj N, Burgess MA, Young S, and Benjamin RS: Phase I-II Trial of Intracarotid Cis-DDP in Patients with Intracerebral tumors. *Amer. Soc. of Clinical Oncology* 1982.
10. Feun LG, Savaraj N, Bedikian AY, Leavens M, Burgess MA, Lu K, Smith RG, Benjamin RS, and Bodey GP: Phase II Study of AZQ in Recurrent Malignant Gliomas. *Amer. Assoc. of Cancer Research* 1982
11. Feun, LG, Gutterman J, Quesada J, Stewart DJ, Leavens M, Burgess MA, and Benjamin RS: Phase I Study of Interferon Administered via Indwelling Ommaya Reservoir for the Treatment of Progressive Malignant Gliomas. 13th International Cancer Congress Abstract 1982.
12. Savaraj N, Lu K, Raulston GL. Feun LG, Burgess MA, and Loo TL: A Comparison of the Pharmacokinetics of Tissue Distribution Between DHAD and HAD in Beagle Dogs. 13th International Cancer Congress Abstract 1982.
13. Lu K, Savaraj N, Feun LG, Leavens ME, and Loo TL: Clinical Pharmacology and Intracerebral Tumors Penetration of VP-16. *Proc. Clin. Pharm. Therapy.* 31:245, 1982.
14. Guo Z, Savaraj N, Smith R, Feun LG, Lu K, Leavens ME, and Loo TL: Clinical Pharmacology of PCNU. *Proc. Clin. Pharm. Therapy.* 31:232, 1982.
15. Stewart DJ, Benjamin RS, Luna M, Yeun K, Leavens M, Feun LG, Yap HY, and Loo TL: Human Tissue Vinblastine and Cis-Platin. *Proc. Amer. Assoc. of Cancer Research* 23:125, 1982.
16. Savaraj N, Lu K, Raulston GL, Feun LG, and Loo TL: Comparison of CNS Penetration Tissue Distribution and Pharmacology of VP-16 Intracarotid vs Intravenous in Dog. *Proc. Amer. Assoc. of Cancer Research* 23:201, 1982.

17. Zhengang G, Stewart DJ, Lu K, Savaraj N, Leavens ME, Feun LG, Benjamin RS, and Loo TL: Tumor Penetration of AMSA in Man. Proc. Amer. Soc. of Clinical Oncology 1:17, 1982.
18. Guo ZG, Lu K, Savaraj N, Feun LG, Huang MT, and Loo TL: Pharmacology Fate of AZQ by Intracarotid or Intravenous Administration in Beagles. Amer. Assoc. of Cancer Research 23:218, 1982.
19. Feun LG, Stewart DJ, Benjamin RS, Leavens M, Luna M, Savaraj N, Yung WKA, Seifert W, and Loo TL: The Pharmacologic Basis for Brain Tumor Therapy in Man with Cis-DDP. Third Southeast Asian and Western Pacific Regional Meeting of Pharmacologists 1:33, 1982.
20. Savaraj N, Lu K, Feun LG, Benjamin RS, and Loo TL: Clinical Pharmacology of New Antitumor Agents. Third Southeast Asian and Western Pacific Regional Meeting of Pharmacologists 1:30, 1982.
21. Lu K, Savaraj N, Yap BS, Huang MT, Burgess MA, Feun LG, Guo Z, and Loo TL: High Performance Liquid Chromatography (HPLC) of the New Antineoplastic 9,10-Anthracenedicarboxaldehyde Bis (4,5-Dihydro-1-H-Imidazole-ZYE) hydrazone Dihydrochloride (CL 216, 942; Bisantrene; NSC-337766). 13th International Cancer Congress Abstract 1982.
22. Loo TL, Lu K, Savaraj N, Feun LG, and Zhengang G: Pharmacology of New Anticancer Drugs. Third Southeast Asian and Western Pacific Regional Meeting of Pharmacologists 1:29, 1982.
23. Zhengang G, Lu K, Savaraj N, Feun LG, Loo TL: Pharmacokinetics of the New Anticancer Agent AZQ by Intracarotid as Compared with Intravenous Administration in the Beagle Dog. Third Southeast Asian and Western Pacific Regional Meeting of Pharmacologists 1:31, 1982.
24. Savaraj N, Feun LG, Lu K, Lee FH, Wallace S, and Loo TL: Clinical Pharmacokinetics of Intracarotid (ic) VP-16 in Primary and Metastatic Brain Tumors. Proc. Amer. Soc. of Clinical Oncology 2:167, 1983.
25. Guo ZG, Savaraj N, Lu K, Feun LG, Burgess MA, Benjamin RS and Loo TL; Tissue and Tumor Penetration of 3-amino-1,5-dihydro-5-methyl-1-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'- monophosphate (TCN-P, NSC-280s594) in Man. Proc. Amer. Soc. of Clinical Oncology 2:41,1983.
26. Lu K, Savaraj N, Feun LG, Benjamin RS, Hester JP, and Loo TL: Clinical Pharmacology of 3-amino, 1,5-dihydro-5-methyl-1-B-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene5'-monophosphate (TCN-P, NSC-280594). Amer. Soc. of Clinical Oncology 2:34, 1983.

27. Guo AZ, Lu K, Savaraj N, Feun LG, Raulston GL, Chan J, and Loo TL: Pharmacokinetic Interaction Between Doxorubicin and Mitoxantrone in the Dog. Proc. Amer. Assoc. of Cancer Research 24:257,1983.
28. Savaraj N, Lu K, Feun LG, Raulston GL, Gray KN, and Loo TL: Comparative Pharmacology of 3-amino-1, 5-dihydro-5-methyl-1-B-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene (TCN, NSC-154020) and its 5'-monophosphate (TCN-P, NSC-280594) in Dogs. Amer. Assoc. of Cancer Research 24:290, 1983.
29. Lu K, Savaraj N, Feun LG, Guo ZG and Loo TL: Pharmacokinetics of Homoharringtonine (HHT, NSC-141633) in Dogs. Proc. Amer. Assoc. of Cancer Research 24:289, 1983.
30. Feun LG, Yap BS, Benjamin RS, Savaraj N, Burgess MA, Ajani JA, McKelvey E, and Bodey GP: Phase I trial of 1,4,5,6,8-Pentaazaacenaphthylene, 3-amino, 1,5-dihydro-5-methyl-1-B-D-ribofuranosyl-5'-phosphate Ester (TCN-P, NSC-280594) on a 5-Day Continuous Infusion Schedule. Proc. Amer. Assoc. of Cancer Research 74:144,1983.
31. Tang R, Prager TC, Mewis L, Zarco I, and Feun LG: Ocular Toxicity and Cis-Platin (Chemotherapy Drug). Assoc. for Research in Vision and Ophthalmology 1983.
32. Feun LG, Wallace S, Lee F, Levens ME, Savaraj N, Yung WKA, Cuang V, Burgess MA, Benjamin RS, and Fields WS: Phase I Trial of Intracarotid VP-16-213 (Etoposide) in Patients with Intracerebral Tumors. Proc. Amer. Soc. of Clinical Oncology 2:238,1983.
33. Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Levens ME, Burgess MA, Savaraj N, Benjamin RS, Tang RA, and Fields WS: Intracarotid Cisplatin in the Treatment of Recurrent Malignant Brain Tumors. The Fourth Asian-Oceanian Congress of Radiology 1:432, 1983.
34. Savaraj N, Wallace S, Feun LG, Lee Y, Lu K, Yung WA, Lee F, Levens ME, Chuang V, and Loo TL: Intracarotid VP-16: Pharmacologic Basis and Early Results of Clinical Trial. The Fourth Asian-Oceanian Congress of Radiology 1:433, 1983.
35. Plunkett W, Nowak B, Feun LG, Benjamin RS, Keating M, and Freireich EJ: Modulation of Arabinosyladenine Metabolism by 2'-Deoxycytosine in the Therapy of Human Acute Leukemia. Fourth Internat. Symp. Human Purine and Pyrimidine Metabolism, 1983.
36. Savaraj N, Lu K, Dimery I, Feun LG, Burgess MA, Guo Z, Chawla S, and Loo TL: Clinical Pharmacology of Homoharringtonine (HHT). Proc. Amer. Soc. of Clin. Oncol. 25:38, 1984.
37. Feun LG, Wallace S, Yung WKA, Lee Y, Levens M, Moser R, Burgess MA, Savaraj N, Tang R, and Fields WS: Phase I-II Trial of Intracarotid (IC) BCNU and cisplatin in patients with Intracerebral Tumors (ICT). Proc. Amer. Soc. of Clin. Oncol. 3:255, 1984.

38. Feun LG, Savaraj N, Lu K, Fields WS, Sutton CH, and Loo TL: Disruption of the Blood Brain Barrier (BBB) with Intracarotid Hydroxyurea(HU).Proc. Amer. Assoc. of Cancer Research 25:364, 1984.
39. Savaraj N, Wright K, Charnsagavej C, Wallace S, Feun LG, and Lu K: Pharmacokinetics of 5-Fluor-2'-Deoxyuridine (FUdR) by Arterial Occlusion Infusion(AOI) or Regional Isolation Perfusion(RIP)in The Dog. Proc.Amer. Assoc. of Cancer Research 25:364, 1984.
40. Obbens, EAMT, Feun LG, Leavens ME, Savaraj N, Stewart DJ, and Gutterman JU: Interferon in the Treatment of Intracranial Malignancies:A Pilot Study. Neurology 34 (Suppl 1):232, March 1984.
41. Lu K, Savaraj N, Kavanagh J, Benjamin RS, Feun L, Burgess M, Bodey G, and Loo TL: Clinical Pharmacology of 4-Demethoxy-Daunorubicin (DMDR). Proc. Amer. Soc. Clin. Oncol. 3:38, 1984.
42. Moser RP, Yung W-KA, Leavens ME, and Feun LG: Clinical-Pathological Correlation in Recurrent Malignant Gliomas. J. of Neuro-Oncology 2:269, 1984.
43. Feun LG, Lee YY, Yung WKA, Charnsagavej C, Savaraj N, Tang R, and Wallace S: Intracarotid (IC) Infusion of Cisplatin (DDP) Chemotherapy Advances in Regional Cancer Therapy. p. 57, 1985.
44. Lu K, Savaraj N, Feun LG, Charnsagavej C, Wallace S, and Loo TL: Clinical Pharmacology of Intra-arterial (IA) Cisplatin (CDDP). Proc. Am. Soc. Clin. Oncol. 4:51, 1985.
45. Savaraj N, Lu K, Feun LG, Leavens M, Moser R, and Loo TL: Central Nervous system (CNS) Penetration of Homoharringtonine (HHT). Proc. Am. Soc. Clin. Oncol. 4:50, 1985.
46. Feun LG, Savaraj N, Lu K, Wang DC, Robbins VW, Stevens LC, Fields WS and Loo TL: Effects of Activated Charcoal in the Pharmacokinetics and Toxicities of Cisplatin (CDDP). Proc. Am. Assoc. Can. Res. 26:263, 1985.
47. Savaraj N, Lu K, Feun LG, Wang D, and Loo TL: Interaction of [3H] Homoharringtonine (HHT) with the Calcium Antagonist Receptor in the Rat. Proc. Am. Assoc. Can. Res. 26:359, 1985.
48. Wang DC, Savaraj N, Lu K, Feun LG, Gray K, and Loo TL: Comparison of CSF Penetration of VP-16 by Intracarotid (IC) Intravenous (IV),and Intraventricular Route (IT) in Dogs. Proc. Am. Assoc. Can. Res., 1985.

49. Lu K, Savaraj N, Feun LG, Newman RA, Robbins VW, Gray KN and Loo TL: Pharmacokinetics of Caracemide (CAR NSC -253272) in Dogs. Proc. Am. Assoc. Can. Res., 1985.
50. Feun LG, Lee YY, Yung W-KA, Charnsangavej C, Savaraj N, Tang R, and Wallace S: Phase II trial of intracarotid BCNU and Cisplatin in Malignant Brain Tumor. Proc. Am. Soc. Clin. Oncol. 4:150, 1985.
51. Feun LE, Martinez J, Lee YY, Yung WKA, Charnasangavej C, Savaraj N, and Wallace S: Phase I and Pharmacokinetic Study of Intracarotid (IC) Cisplatin and Bleomycin in Malignant Brain Tumors. Proc. Am. Assoc. Can. Res. 27:189,1986.
52. Feun LG, Savaraj N, Legha S, Silva EG, Benjamin RS, and Burgess MA: Chemotherapy for Metastatic Merkel Cell Carcinoma: Review of MD Anderson Hospital's Experience. Proc Am Soc Clin Oncol 5:145,1986.
53. Savaraj N, Feun L, and Sevin B: Pharmacokinetics and Cellular Concentration (CONC) of Cisplatin (DDP) by Intraperitoneal (IP) Route. Proc. Am. Soc. Clin. Oncol. 6:34, 1987.
54. Feun L, Sevin B, Savaraj N, Berndhart S, Davila E, Benedetto P, and Averette H: Clinical and Pharmacologic Study of Intraperitoneal (IP) Chemotherapy (CT) with Cytarabine (Ara-C) and Cisplatin (DDP) in Patients (Pts) with Peritoneal Carcinomatosis. Proc. Am. Soc. Clin. Oncol. 6:133, 1987.
55. Lu N, Savaraj N, Feun L, and Loo TL: Comparison of Pharmacokinetics of Cis-diamminedichloroplatinum by Intraperitoneal (IP) Route and Intravenous (IV) Route in Solid Tumor Patients. Proc. Am. Soc. Clin. Pharm. and Therapeutics, 1987.
56. Sridhar KS, Samy A, Kosinski J, Benedetto P, Feun L, Gruss J, Owen P, and Zubrod CG: A Phase I Study of IV Bolus Q3W 4'-O-Tetra-Hydropyranyl-Adriamycin (THP-ADM) Chemotherapy. Proc. Am. Soc. Clin. Oncol. 6:28, 1987.
57. Lu K, Savaraj N, Feun L, and Loo TL: The Interaction of 4'-O-Tetrahydropyranyl Adriamycin and Homoharringtonine. Proc. Am. Assoc. Can. Res., 1987.
58. Feun LG, Lee YY, Plager C, Papadopoulous N, Savaraj N, Diaz RD, CharnSangavej C, Burgess MA, Benjamin RS, and Wallace S. Intracarotid Chemotherapy for Patients with Melanoma and Brain Metastases. International Conference on Advances in Regional Cancer Therapy.
59. Feun LG, Clendeninn NJ, Savaraj N, Benedetto P, Sridhar K, Hanlon J, Collier M, and Richman S. Phase I Trial of Piritrexim (BW 301, PTX) Capsules using Prolonged Low-Dose Administration. Proc Am Assoc Can Res, 1988.
60. Serafini AN, Kotler J, Feun L, Robinson D, Chattopadhyay K, Heal A, Dewanje M, Ganz W, Sfakianakis G, Abrams P, and Nel W. Specific Tc-99m-Labeled Antimelanoma

Murine Monoclonal Antibody (NR-ML-05) Scintigraphy in Patients with Malignant Melanoma. *European Journal of Nuclear Medicine* 14: 232, 1988.

61. Serafini AN, Kotler J, Feun L, Heal A, Dewanjee M, Friden A, and Abrams P. Tc-99m Labeled Monoclonal Antibodies in the Detection of Metabolic Melanoma (MM)-Clinical Experience in a Phase III Study. *Proc Soc of Nuclear Medicine*, 1988.
62. Feun L, Kotler J, Serafini A, Savaraj N, Robinson D, Ketcham A, Fritzberg AR, East D, and Abrams P. Anti-melanoma Tc 99m FAB Antibody for Imaging Metastatic Melanoma (MM). *Proc Am Soc Clin Onc*, 7:249, 1988.
63. Savaraj N, Luk Tsao J, Castella C, Lampidis T, Feun L, and Loo TL: Induction of Differentiation and Down Regulation of C-myc RNA Expression in K 562 cell lines by Homoharringtonine. *Proc Am Assoc Can Res.*, 1988.
64. Kotler J, Serafini A, Feun L, Heal A, Dewanjee M, Friden A, East D, and Abrams P. Imaging Melanoma with Anti-melanoma Tc-99m Fab Antibody. *Proc Monoclonal Workshop*, 1988.
65. Ganz WI, Feun L, Panzer D, Johnson G, Medina A and Brandon A. Application of SPECT Thallium Scintigraphy in the Imaging of Primary and Metastatic Brain Tumors. *Radiology* 169(p):392, 1988.
66. B Ardalan, A Hussein, L Sklaver, R Reddy, P Benedetto, K Sridhar, S Richman L Feun, N Savaraj, S Waldman, S Hung: Chemotherapy of advanced carcinoma with 5-Fluorouracil and Leucovorin. *Proc Soc Clin Oncol* 8:116,1989.
67. RP Whitehead KR Kopecky, MK Samson, JJ Costanzi, R. Natale, L Feun EM Hersh.A Phase II Study of IV Bolus Recombinant Interleukin(IC-2)in Metastatic Malignant Melanoma: A Southeast Oncology Group Study. *Proc Am Soc Clin Oncol* 8:284, 1989.
68. L Feun H Landy K Lu, DJ Li, MT Kuo, T Lampidis, B Green and N Savaraj MDR1 Gene Expression in Primary Malignant Brain Tumor (MBT). *Proc Am Soc Clin Oncol* 8:88, 1989.
69. N Savaraj,K Lu, J Taso, L Feun, DJ Li, T Lampidis, E Donnelly, J Patten and M Kuo. MDR1 mRNA Expression in Small Cell Lung Cancer Patients. *Proc Am Soc Clin Oncol* 8:246, 1989.
70. K Lu, N Savaraj, J Yau, D Li, T Kuo L Feun, and EJ Freireich In Situ Hybridization for MDR1 mRNA Expression in the Detection of Tumor Cell Heterogeneity. *Proc Am Assoc Can Res* 1989.
71. N Savaraj, T Lampidis, H Levin, H Landy, S Waldman and L Feun. Phase II Study of Homoharringtonine and In Vitro Chemotherapy Sensitivity Testing in Primary Malignant Brain Tumor. *Proc Am Assoc Can Res* 30:274,1989.

72. Serafini AN, Feun L, Fayad F, Robinson D, East D, Salk D, Dewanjee M, Suppers, V, Abrams P. Detectability of Metastatic Melanoma with Tc99m-Monoclonal Antibody Fragments, South African Medical Journal 75:134, 1989.
73. Feun LG, Robinson WA, Savaraj N, Hanlon J, Collier M, and Clendeninn NJ. Phase II Trial of Piritrexim (BW 301, PTX) Capsules in Metastatic Melanoma(MM) using Prolonged Low-Dose Administration. Proc Am Assoc Can Res 30:273,1989.
74. Clendennin NJ, Collier MA, Feun LG, Robinson WA. Prolonged Low Dose Administration of Piritrexim (PTX), A Better Way to Deliver an Antifolate? Proc. Sixth NCI-GORTC Symposium, Amsterdam, Netherlands, 1989:481.
75. Sridhar KS, Thurer RJ, Savaraj N, Benedetto P, Feun L, Waldman S, Schwade J. Pre and Post-operative(OP) Adjuvant Chemotherapy (CT) in Locally Advanced Non-Small Cell Lung Carcinoma (NSCLC) Proc Am Soc Clin Oncol 8:237, 1989.
76. Lu K, Savaraj N, Yau J, Li D, Kuo T, Feun L and Freireich ET. In Situ Hybridization for MDR-1 mRNA Expression in the Detection of Tumor Cell Heterogeneity. Proc Am Assoc Can Res 30:417, 1989.
77. Ganz WI, Feun LG: Craniotomy sites as potential false-positive areas of tumor in: SPECT brain scintigraphy. Radiology 173 P:498, 1989.
78. Ganz WI, Feun L, Sfakianakis GN, Serafini An, Jabir AJ, Karavelis A, Rodriguez R, Tau F, Landy H. SPECT thallium and Tc-HMPAO comparison studies in brain tumors. Soc Nuclear Med, 1990.
79. Savaraj N, Wu CJ, Lampidis T, Feun L. Effects of granulocyte macrophages colony stimulating factor(GM-CSF)or cell growth and cytotoxicity of small cell lung cancer and glioma cell lines. Proc Am Assoc Can Res 1990.
80. Savaraj N, Feun L, Wu CJ, Chua L,Legaspi A, and Lu K. Proto-organic expression in human osteogenic osteosarcoma and soft tissue sarcoma. Molecular Basis of Cancer 1990.
81. Ganz WI, Tow, F, Landy H, Feun, L.Craniotomy sites in potential false-positive areas of tumor in SPECT brain scintigraphy. Soc Nuclear Med. 1990.
82. Yuan K, Wellham L,Sauerteig A, Feun LG and Krishan A. Doxorubicin retention and cytotoxicity in human melanoma cells. Proc Am Assoc Can Res 31:373, 1990.
83. Feun LG, Blyden G, Dorvil M, Benedetto P, Yrizarry JM, Donnelly E, Curtas J, Sridhar KS, Waldman S, DeLap R and Savaraj N. Clinical and pharmacological study of intrahepatic infusion of Thiotepa. Proc Am Assoc Can Res 31:178,1990

84. Savaraj N, Blyden G, Dorvil M, Yrizanny JM, Donnelly E, Post J, Curtas J, Waldman S, Benedetto P and Feun LG. Clinical and pharmacological study of intra-carotid (IA) infusion of Thiotepa in localized extrahepatic tumors (LET). Proc Am Soc Clin Oncol 9:87, 1990.
85. Feun LG, Savaraj N, Landy HJ, Lu K, Green B, Page L, Rosomoff H and Lampidis T. Molecular biology of primary brain tumors. Proc Am Soc Clin Oncol 9:96, 1990.
86. Sridhar KS, Hussein AM, Barmann A, Benedetto P, Ardalan B, Waldman S, Richman SP, Feun LG, Savaraj N, Morrell L and Donnelly E. Phase II study of Q 3 week IV bolus Pirarubicin (4'0 Tetrahydropyranyladriamycin) in head and neck carcinoma (H&NCA). Proc Am Soc Clin Onc 9:179, 1990.
87. Ardalan B, Palmieri M, Reddy R, Sridhar K, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A. A Phase I study of short term protracted interferon with low dose 5-Fluorouracil (5FU), high dose Leucovorin (LV) with low dose N-(Phosphonacetyl)-aspartic acid (PALA). The Seventh Intl. Conference on Chemical Modifiers.
88. Feun LG, Maor M, Stewart DJ, Leavens Me, Yung WK, Savaraj N, Burgess MA. Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas. Clinical Digest Series.
89. Hung S, Hilsenbeck S, Feun L. Seizure prophylaxis with phenytoin in patients with brain metastases. Proc Am Soc Clin Oncol 1991.
90. Feun LG, Lee YY, Plager C, Papadopoulos N, Savaraj N, Charnsangavej C, Benjamin RS, and Wallace S. Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases-Clinical Digest Series.
91. Hussein AM, Feun L. Tumor lysis after induction chemotherapy in small cell lung carcinoma. Oncology Digest 1:21-22, 1991.
92. Feun L, Wu CJ, Chua L, Lampidis T, and Savaraj N. In vitro antitumor activity of U73,975 in multidrug resistant and cisplatin resistant cells. Proc Am Assoc Can Res 32:404,1991.
93. Wu CJ, Purulbe V, Lampidis T, Feun, L, Blyden G, and Savaraj N. Characteristics of cisplatin-resistant human small cell lung cancer. Proc Am Assoc Can Res 32:369,1991.
94. Clendeninn NJ, Savaraj N, Benedetto P, Waldman S, Antunez J, Donnelly E, Offenhauser K, and Feun LG. Compassionate use of oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy: Proc Am Assoc Can Res. 32:186,1991.

95. Ardalan B, Sridhar K, Richman S, Benedetto P, Morrell L, Feun L, Savaraj N, Waldman S. Addition of high dose leucovorin (LV) to high dose infusion of 5-Fluorouracil (5-FU) and low dose PALA: Effective in pancreatic cancer. Proc Am Soc Clin Onco. 10:139,1991.
96. Sridhar KS, Krishan A, Anac S, Duncan R, Benedetto P, Ardalan B, Samy T, Feun L, Savaraj N, Richman S. Phase I study of doxorubicin plus prochlorperazine as a resistance modifier. Proc. Am. Soc. Clin. Onco. 1991.
97. Landy H, Feun L, Ku K, Lampidis T, and Savaraj N. Multiple Drug Resistance Gene Expression in Gliomas. Proc Am Assoc Neuro Surgeons,1991.
98. Feun LG, et al "Pilot Study of PCNU and cranial radiation therapy in treatment of patients with malignant gliomas". Oncology Digest 2:16-17, 1991.
99. Morrell L, Ardalan B, Richman S, Waldman S, Feun L., Sridhar S, Benedetto P. A Phase II study of thiotepa in combination with 5FU and LV in patients with advanced breast cancer. Proc Am Soc Clin Oncol 10:62,1991.
100. Savaraj N, Landy H, Wu C, Green B, Page L, Villanueva P, and Feun L. Oncogene expression in central nervous system (CNS) tumor. Proc Am Soc Clin Oncol 10:129, 1991.
101. Feun LG, Savaraj N, Benedetto P, Sridhar K, Hanlon J, Collier M, Richman S, and Clendennin N. Phase I trial of Piritrexim capsules using prolonged, low-dose administration. Pharmacy Digest 1:25-26, 1991.
102. Ganz WI, Feun L, Sfakianakis GN, Serafini AN, Jabir AM, Landy H: SPECT thallium and Tc-HMPAO studies in brain tumors. Greater New York Society of Nuclear Medicine,
103. Sixteenth Annual Meeting Proceedings 16:19, 1990.
104. Milam AH, Saar JC, Feun LG, Jacobson SG. Cutaneous melanoma associated retinopathy. International Society for Eye Research, 1992.
105. Morrell L, Richman S, Waldman S, Hurley J, Otrakji C, Sridhar KS, Benedetto P, Feun L, Ardalan B, Donofrio K, Liebman A, Hanlon J. Methotrexate, Vinblastine, Doxorubicin, Cisplatin (MVAC) as neoadjuvant for locally advanced breast cancer. Proc Am Soc Clin Onc 11:84, 1992.
106. Savaraj N, Feun L, Shirley L, Hung S, Donnelly E, and Hsu T. Cytogenetic analysis as a biological marker in predicting myelosuppression from chemotherapy. Proc Am Soc Clin Oncol 11:98,1992.
107. Tian E, Ardalan B, Benedetto P, Feun L, Morrell L, Waldman S, Hurley J, Savaraj N, Richman S, Livingstone A, Anac S. A phase II study of short term infusion of

high dose 5-Fluorouracil (5-FU) with Leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in pancreatic carcinoma. Proc Am Soc Clin Oncol 11:184,1992.

108. Ardalan B, Donofrio K, Sridhar KS, Feun L, Savaraj N, Benedetto P, Morrell L, Waldman S, Reddy R, Livingstone A. Is there hope after 5-FU-bolus? A phase II study of short term protracted infusion of high dose 5-Fluorouracil (5-FU) with Leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in colorectal carcinoma. Proc Am Soc Clin Oncol 11:186, 1992.
109. Feun LG, Raub Jr W, Duncan RC, Moffatt F, Savaraj N, Nemeth A, and Markoe A. Melanoma within a Southeastern Hispanic Population. Proc Am Soc Clin Oncol 11:349, 1992.
110. Wu CJ, Feun L, Lampidis TJ and Savaraj N. Induction of multidrug resistance (MDR) in cisplatin resistant cells and induction of cisplatin resistance in MDR cells. Proc Am Assoc Can Res 33:457, 1992.
111. Savaraj N, Wu CJ, Lampidis TJ and Feun L. Comparison of antitumor activity of U7397S, U77779 and U80244 in multidrug resistant and cisplatin resistant cells. Proc Am Assoc Can Res 33:489, 1992.
112. Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ, Purser RK, Waldman S, Moffatt F, Morrell L, Ardalan B and Benedetto P. Phase I hepatic chemoembolization trial with cisplatin and lipiodol. Proc Am Assoc Can Res 33:230, 1992.
113. Feun LG, Savaraj N, Benedetto P, Reddy R, Jeffers L, Schiff E, Levi J, Livingstone A, Sridhar KS and Hung S. Phase II trial of leukocyte interferon plus doxorubicin in advanced hepatoma. Proc Am Assoc Can Res, 1993.
114. Feun LG, Savaraj N, Moffat F, Robinson D, Liebman A, Hurley J, Clark K, and Richman SP. Phase II trial of recombinant alpha-interferon (IFN) with BCNU, DTIC, Cisplatin (DDP) and Tamoxifen (TAM) in advanced, malignant melanoma. Am Soc Clin Oncol 1993.
115. Savaraj N, Wu CJ, Donnelly E, Solomon J, Lampidis TJ, Chua L, and Feun LG. Multidrug resistant gene expression in small cell lung cancer. Am Assoc Can Res 1993.
116. Wu CJ, Landy H, Savaraj N, Sternau L, Lampidis T, and Feun LG. Molecular genetics of malignant glioma. Proc Am Assoc Can Res,1993.
117. Chatoor H, Sridhar K, Benedetto P, Feun LG, Reddy R, Livingstone A, Donofrio K, Elie-Auguste M, Tejada F and Ardalan B. Phase I study of 24h infusion of 5-fluorodexoyuridine (FUDR) with pharmacokinetics. Proc Am Assoc Can Res 1993.

118. Savaraj N, Wu CJ, Donnelly E, Solomon J, Lampidis TJ, Feun L, and Kuo MT. MDR gene expression in small cell lung cancer in General Motors Symposium on Drug Resistance, Toronto, Canada, 1993.
119. Flores MR, Morrell L, Richman S, Waldman S, Hurley J, Mies C, Benedetto P, Feun L, Donofrio K, Liebman A, Hanlon J, Cassileth P. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for locally advanced breast cancer
120. (LABC) Proc Am Soc Clin Oncol 12:102, 1993.
121. Ganz WI, Feun L, Sfakianakis GN, Serafini AN, Jabir AJ, Karavelis A, Rodriguez R, Tow F and Landy H. Thallium and Tc-HMPAO companion study in thallium SPECT
122. brain scintigraphy 1994.
123. Wu CJ, Bao JJ, Teeter L, Kuo MT, Lampidis TJ, Feun L, Chua L, Savaraj N. Characteristics of two resistant small cell lung cancer lines with increased multidrug resistant associated protein gene expression. Proc Am Assoc Can Res 35:466, 1994.
124. Savaraj N, Wu CJ, Bao JJ, Solomon J, Donnelly E, Feun LG, Lampidis TJ, and Kuo MT. Multidrug resistance associated protein gene expression in small cell and non-small cell lung cancer. Proc Am Assoc Can Res 35:242, 1994.
125. Tian E, Donofrio K, Sridhar KS, Feun LG, Morrell L, Richman SP, Benedetto P, Chatoor H, and Ardalan B. Phase I study of 24 infusion of 5-fluorodeoxyuridine (FUDR) with pharmacokinetics. Proc Am Assoc Can Res 35:244, 1994.
126. Schwade JG, Raub Jr., WA, Feun LG, Green B, Markoe A, Landy H, Snodgrass S. Descriptive epidemiologic analysis of Jackson Memorial Hospital tumor registry experience for primary spinal cord tumors. Proc Am Assoc Can Res 35:288, 1994.
127. Feun L, Landy H, Wu CJ, Bao JJ, Teeter L, Kuo MT, Sternan L, and Savaraj N. Multidrug resistant associated protein (MRP) gene expression in primary brain tumor. Proc Am Soc Clin Oncol 13:182, 1994.
128. Savaraj N, Xu R, Wu CJ, Landy HJ, and Feun L. Cytotoxic effect of novel 21'-amino steroid U-74500 A alone and in combination with cisplatin in human glioma cells. Proc Am Soc Clin Oncol 13:179, 1994.
129. Mammolenti M, Baker M, Feun L, Podack ER and Levy RB. Co-culture of IL-2 transjected human melanoma lines with PBMC induces functional LAK activity in vitro. Fed Soc Exp Biol 1995.
130. Landy HJ, Markoe A, Houdek PV, Feun LG and Mallin W. Thallium SPECT in assessment of glioma response to radiosurgery. 2nd Congress of Intl Stereotactic Radiosurgery Society, 1995.

131. Mammolenti M, Baker, Feun L, Podcak ER, Levy RB. Co-culture of IL-2 transfected human melanoma lines with autologous PBMC induces LAK activity against autologous untransfected melanoma cells in vitro. 9th Int Congress of Immunology.
132. Ardalan B, Sridhar KS, Feun LG, Richman SP, Donofrio K, Watson C. Phase I study of 24-hour infusion of 5-Fluorodexoyuridine (FUdR) with pharmacokinetics. Proc Am Assoc Clin Res 36:237, 1995.
133. Wu CJ, Kuo MT, Xu R, Lampidis T, Feun L and Savaraj N. Small cell lung cancer selected for multidrug resistance with Rhodamine-123. Proc Am Assoc Cancer Res 36:332, 1995.
134. Feun L, Xu R, Savaraj N, Sternau L, Solomon J and Landy H. Topoisomerase I & II levels in human brain tumors. Proc Am Assoc Can Res 36: 448, 1995.
135. Savaraj N, Xu R, Wu CJ, Solomon J, Chua L, Lampidis TJ and Feun LG. Topoisomerase I & II levels in non-small cell and small cell lung cancer patients. Proc Am Assoc Can Res 36:448, 1995.
136. Mammolenti M, Gutgsell N, Feun LG, Podack ER, and Levy RB. Expression and Regulation of of FAS on Human Melanoma Cell Lines. ASBMB 1996.
137. Feun L, Raub, Jr, W, Moffat F, Markoe A, Robinson D, Savaraj N, Iriondo M. A Prospective Case-Control Epidemiological Study of Malignant Melanoma in South Florida. Proc Am Soc Clin Onc 14:416, 1995.
138. Savaraj N, Xu R, Wu CJ, Landy H, Chun L, Solomon J and Feun L. Correlation of In-Vitro Antitumor Activity of Irinotecan and Topoisomerase I Activity and Levels in Brain Tumors. Proc Am Soc Clin Oncol 14:482, 1995.
139. Ardalan B, Donofrio A, Livingstone R, Reddy R, Richman S, Sridhar KS, Benedetto P, Morrell L, Miller CL, Feun L. A Phase II Study of Weekly Low Dose Bolus Phosphonacetyl-L-Aspartic Acid (PALA) and 24-Hour Infusion with High-Dose Fluorouracil (5FU) with Leucovorin (LV) in Colorectal Cancer. Proc Am Soc Clin Onc 14:220, 1995.
140. Ardalan B, Restrepo A, Deng Z, Sridhar KS, Feun L, Richman S, Sparling L, Watson C, Triplett N. Phase I-II Trial of High Dose 24-Hour Infusion of Fluorodeoxyuridine (FUdR) in Patients with Colorectal Cancer (Previously failed 5-Fluorouracil). Proc Am Soc Clin Onc 15:202, 1996.
141. Khorsand M, Lange J, Feun L, Clendeninn N, Collier M, Wilding G. Phase II Trial of Oral Piritrexim in Advanced, Previously Treated Transitional Cell Cancer of Bladder. Proc Am Soc Clin Oncol 15:297,1996.

142. Feun LG, Reddy KR, Yrizarry JM, Guerra JJ, Bernstein D, Jeffers LJ, Ardalan B, Livingstone A, Love J, Savaraj N, Hurley J, Murray T, Scagnelli T. Phase I-II Trial of Lipiodol Chemoembolization (LCG) with Cisplatin (DDP) and Thiotepa (TT). Proc Am Soc Clin Oncol 15:211, 1996.
143. Savaraj N, Xu R, Landy H, Wu CJ, Solomon J, Feun LG. Correlation of Cytotoxic Effect of Vitamin (Vit) D and Vit D like receptor in Human Brain Tumors. Proc Am Soc Clin Oncol 15:154,1996.
144. Feun L, Savaraj N, Liebmann A, Hurley J, Hohneker JA. Phase II Trial of Intravenous Navelbine and Oral Tamoxifen in Advanced, Malignant Melanoma. Proc Am Soc Can Res, 1996.
145. Savaraj N, Wu C, Xu R, Lampidus T, Feun L, Kao M. Characteristics of Cisplatin/Adriamycin Resistant Small Cell Lung Cancer Cell Lines. Proc Am Soc Can Res, 1996.
146. Fragulidis G, Nery J, Khan M, Wepler D, Ciancio G, Burke G, Morales A, Feun L, Miller J, and Tzakis A. Orthotopic liver transplantation for liver tumors. 19th Panhellenic Surgical Congress, Athens, Greece, A20:45,1996.
147. Wu CJ, Feun L, Xu R, Lampidus T, Chua L, Savaraj N. Quantitation Multidrug Resistance Associated Protein (MRP) Gene Expression by Competitive Reverse-Transcriptase-Polymerase Chain Reaction (RT-PCR). Proc Am Soc Can Res, 1996.
148. Landy HJ, Mallin WH, Markoe AM, Houdek PV, Feun LG. Thallium-201 SPECT in Assessment of Glioma Response to Radiosurgery. Soc Nuclear Med 1997.
149. Prados M, Schold C, Fine H, Jaeckle K, Hochberg F, Mechtler L, Fetell M, Phuphanich S, Feun L, Janus T, Downing G, Wortel C. Randomized Placebo Controlled Phase II Study of IV Carboplatin with or without IV RMP-7 in Patients with Recurrent Malignant Glioma. - Second Annual Meeting of Neuro-Oncology, 1997.
150. Ardalan B, Sparling L, Livingstone A, Francheschi D, Sridhar KS, Feun LG, Richman SP, Triplett N. Proc Am Soc Clin Oncol 16: 282a, 1997. Phase II trial of High-Dose 24-Hour Infusion of 5-Fluorodeoxyuridine (FUDR) in Patients with Inoperable Pancreatic Cancer Previously Failed 5-FU and Gemzar.
151. Baker L, Khan R, Lynch T, Savaraj N, Sander A, Feun L, Schasser R, Hanover C, Petit R. Phase II study of Irinotecan (CPT-11) in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 16:461a, 1997.
152. Savaraj N, Wu CJ, Xu R, Lai S, Lampidis TJ, Chua L, Feun L. Multidrug Resistant Associated Protein (MRP) gene expression in Lung Cancer. Proc Am Soc Clin Oncol 16:481a,1997.

153. Feun LG, Savaraj N, Schwartz M, Moffat F, Robinson D, Johr R, Spencer J. Phase II Trial of Taxol and DTIC with Filgrastim Administration in Advanced Malignant Melanoma (MM). Proc Am Soc Clin Oncol 16:505a, 1997.
154. Feun L, Savaraj N, Schwartz M, Moffat F, Robinson D, Richman S. Biochemotherapy for Advanced Melanoma: The University of Miami Experience. Proc Am Assoc Can Res 38:223, 1997.
155. Savaraj N, Lampidis TJ, Wu CJ, Xu R, Feun L. Differential Sensitivity to Vinca Alkaloid Analogs in MDR and MRP. Proc Am Assoc Can Res 38:391, 1997.
156. Kuker RA, Serafini AN, Gulec SA, Feun L, Moffatt F, Francheschi D, Spencer J. Comparison of conventional diagnostic methods and octreoscan in malignant melanoma. Soc. Nuclear Med, 1998.
157. Savaraj N, Xu R, Landy H, Wu CJ, Lampidis TJ and Feun L. Probing vitamin D sensitivity in primary brain tumor. Proc Am Assoc Can Res 39:104, 1998.
158. Feun L, Savaraj N, Landy H, Schwartz M. Treatment of recurrent malignant gliomas with mustargen, oncovin, and procarbazine. Proc Am Assoc Can Res 39:502, 1998.
159. Rothenberg ML, Hainsworth JD, Rosen C, Mitchell GP, Henderson CA, Gralla RJ, Rivkins, Loehrer PJ, Hanson JP, Feun LG, Patel RG, Compton LP, Pirutka N, Elfring GG, and Miller LL. Phase II study of Irinotecan 250 mg/m² every other week in previously treated colorectal cancer patients. Proc Am Clin Onc 17:284a, 1998.
160. Feun LF, Blessing JA, Major FJ, Di □ Sala PJ, Alvarez
study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: A gynecologic oncology group study. Proc Am Soc Clin Oncol 17:365a, 1998.
161. Savaraj N, Landy H, Xu R, Ying D, Wu CJ, Lampidus T and Feun L. Relationship of Preprocollagen Type I and Vitamin D Sensitivity in Primary Brain Tumor. Proc AACR 40:162, 1999.
162. Wu CJ, Lampidus T, Xu R, Ying D, Feun L, Chua L, and Savaraj N. Multidrug Resistant Associated Protein (MRP4) Expression in Cisplatin Resistant Lung Cancer Cell Lines. Proc AACR 40:669, 1999.
163. Noy L, Feun L, Marini A, Ardalan B, Reddy R, Savaraj N. A Phase II Trial of Recombinant Leukocyte Interferon, Doxorubicin, and 5-FUDR in Patients with Hepatocellular Carcinoma. Proc Am Soc Clin Oncol 18:295a, 1999.
164. Ardalan B, Sparling L, Sridhar KS, Hurley J, Feun L, Richman S, Hamilton K, Triplett N and Fayad D. Phase II Trial of High Dose 24-Hour Infusion of Fluorodeoxyuridine (FUDR) in Patients with Metastatic Colorectal Cancers (Previously Failed Multiple Chemotherapeutic Modalities). Proc Am Soc Clin Oncol 18:249a, 1999.

165. Feun LG, Wu CJ, Robbies C, Zou JY, Xu R and Savaraj N. In vitro antitumor effect of (-)-1-Epigallocatechin in human tumor cell lines. Proc Am Assoc Can Res 41:534,2000.
166. Savaraj N, Wu CJ, Xu R, Chua L, Robles C, Feun L, Lampidis T, Donnelly E, Anderson M, Furst AJ, Lai SH. Multidrug resistant gene (MDR1) and multidrug resistant associated protein gene expression in small cell lung cancer. Proc Am Soc Clin Oncol 19:487a, 2000.
167. Feun L, Savaraj N, Hurley J, Marini A. Phase II trial of taxol and DTIC with filgrastim administration in advanced malignant melanoma. Final Report. Proc Am Soc Clin Oncol 19:571a, 2000.
168. Feun L, Modiaro M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassiar B, MacDonald S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) using a single intravenous dose schedule. Proc Am Assoc Can Res 42:543,2001.
169. Wu C-J, Landy H, Zou J-Y, Razack N, Xu R, Savaraj N, Robles C, and Feun L. Expression of procollagen-like protein in primary brain tumor. Proc Am Assoc Can Res 42:654,2001.
167. Savaraj N, Wu C-J, Xu R, Lampidis T, Robles C, Chua L, Furst AJ and Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer. Proc Am Assoc Can Res 42: 918,2001.
170. Feun LG, Mazumder A, Marini A, Elgart G, Hurley J, Savaraj N. A pilot study of the initiation of an autoimmune reaction to tumor in melanoma patients by cyclosporin A, alpha interferon and interleukin-2 following chemotherapy with BCNU, DTIC, Cispatin and Tamoxifen. Proc Am Soc Clin Oncol 20:359A, 2001.
171. Grunberg SM, Rankin C, Townsend J, Ahmadi L, Feun L, Fredericks R, Russel C, Kabbavar F, Barger GR, Stelzer KJ. Phase III double-blind randomized placebo-controlled study of Mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 20: 219, 2001.
172. Wangpaichitr, T Lampidis, L Feun, M Sundram, A Furst, C Jing-Wu, C Robles, L Chua, N Savaraj. Expression of procollagen type I correlates with vitamin D sensitivity in sarcoma. Proc Am Assoc Can Res 43:435,2002.
173. Feun, H Landy, M Tienkuo, N Razack, C Jing-Wu, M Wangpaichitr, T Lampidis, AJ Furt, C Robles, N Savaraj. Procollagen-like protein as a molecular target for vitamin D3 in primary brain tumor. Proc Am Assoc Can Res 43:435, 2002.

174. CJ Wu, M Wangpaichitr, LY Yang, R Agarwal, L Feun, T Lampidis, C Robles, and N Savaraj. Collateral sensitivity to nucleoside/purine analogs in cisplatin resistant cell lines. *Proc Am Assoc Can Res* 43:955, 2002.
175. Leung TWT, Feun L, Posey J, Stagg RJ, Levy MD, Venook AP. A Phase II study of T138-sodium in patients with unresectable hepatocellular carcinoma. *Proc Am Soc Clin Oncol* 21:144a, 2002.
176. Raez LE, Cassileth P, Sridhar K, Feun L, Baldie P, Farfan N, Padmanabhan S, Podack E. Novel vaccination in patients with non-small cell lung cancer using an allogeneic adenocarcinoma (Ad 100-B7.1 (CD80/HLA) vaccine. *Proc Am Soc Clin Oncol* 21:3b, 2002.
177. Landy H, Markoe A, Potter P, Marini A, Savaraj N, Reis J, Wangpaichitr M, and Feun L. Radiosurgery (RS) plus estramustine in the treatment of patients with malignant primary brain tumors. *Proc Am Soc Clin Onc* 21:706, 2002.
178. Savaraj N, Wu C, Wangpaichitr M, Lampidis T, Robles C, Rarst NJ, Fein L, Circumvention of drug resistance in small cell lung cancer by mTOR inhibitor. *Proc AACR* 44:847, 2003.
179. Feun LG, Wangpaichitr M, Wu C, Landy H, Lampidis T, Robles C, Savaraj N. New Approach in the treatment of primary brain tumor by targeting growth signaling pathway. *Proc AACR* 44:1506, 2003.
180. Logan T, Feun L, Bomalaski JS, Clark MA, Gastello G, Beneduce G, Scala S, Izzo F, Ascierto PA. Phase I/II testing of pegylated arginine deiminase in metastatic melanoma. *Proc Am Soc Clin Oncol* 22: 710, 2003
181. Feun LG, Marini A, Molina E, O'Brien C, Schiff E, Jeffer L, Savaraj N. Thalidomide as palliative care for patients with unresectable hepatocellular carcinoma. *Proc Am Soc Clin Oncol* 22: 865, 2003.
182. Feun LG, Wu C, Clark M, Bomalaski J, Holtsberg F, Wangpajit M, Robles C, Savaraj N. Mechanism of antitumor effect of arginine deiminase-polyethylene glycol (ADI-PEG20) and the possible mechanism of resistance in melanoma. *Proc Am Assoc. Can Res* 45, 2004.
183. Savaraj N, Wu C, Wangpajir M, Robles C, Lampidis T, Furst A, Feun L. Antitumor Activity of flavopiridol in cisplatin and multidrug resistant small cell and non-small cell lung cancer. *Proc. Am Assoc. Can Res.* 45: 2004.
184. Feun, LG, Marini A, Echenique A, Guerra JJ, Yrizarry JM, Stadtlander K, Savaraj N, Jeffers L, O'Brien C, Schiff E. Phase II study of lipiodol chemoembolization with cisplatin and thiotepa with oral thalidomide for primary liver cancer and liver metastases. *Proc Am Soc Clin Oncol* 23: 346, 2004.

185. Wu C, Wangpaichitr M, Kuo T, Feun LG, Robles C, Furst AJ, Lampidis TJ, Savaraj N. Overcoming cisplatin resistance in lung cancer by inhibiting mTOR. Proc Am Assoc Can Res. 2005.
186. Feun LG, Wei J, Wangpaichitr, Landy H, Kuo T, Robles C, Furst A, Savaraj N, Wu C. Procollagen alpha 1 type 1 as a determinant for vitamin D sensitivity. Proc Am Assoc. Can Res. 2005
187. Porta C, Ruff P, Feld R, Feun L, Jeziorski K, Leighton J, Senico P, Gallo J, Kennealey G. Results of a Phase III randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX). Proc Am Soc Clin Oncol , GI symposium 2006
188. Wu C, Wangpaichitr M, Feun L, Lampidis T. Kuo MT, Robles C, Savaraj N. The mechanisms of mTOR inhibitor overcoming cisplatin resistance. Proc AACR 2006
189. Feun LG, Wu C, Zhang X, Wangpaichitr M, Kuo MT, Pyles A, Bomalaski J, Wu B-W, Holtsberg F, Robles C, Savaraj N. The relationship of arginine deprivation, argininosuccinate synthetase expression and cell death in melanoma. Proc AACR 2006.
190. Feun LG, Savaraj N, Marini A, Wu C, Robles C, Herrera C, Spector S, Luedemann K, Moffat F, Bomalaski J. Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma. Proc ASCO 24: 464s, 2006, Atlanta GA.
191. Feun L., Wu C-J, Lee S, Kuo M-T, Wangpaichitr M, Robles, C, Savaraj N. Potentiation of antitumor effect of DNA damaging agents by arginine deiminase (ADI) in melanoma. Proc AACR. 48: 57, 2007.
192. Savaraj N, Wu C-J, Kuo M-T, Lee S, Wangpaichitr M, Robles C, Feun L. Translation control of argininosuccinate synthetase in melanoma and clinical implications for therapy. Proc AACR 48: 1064, 2007
193. Calfa C, Escalon M, Zafar S, Lopez E, Patel V, Patel S, Feun L, Raez LE. Beyond race: the impact of ethnicity on the treatment outcome of locally advanced head and neck cancer. Proc ASCO 25: 16500, 2007.
194. Savaraj N, You M, Wu C, Marini A, Kuo MT, Wangpaichitr M, Bomalaski J, Feun L. Arginine deprivation for the treatment of advanced melanoma: clinical results/correlation with argininosuccinate expression. Proc Am Soc Clin Oncol 26: 723s, 2008

195. Feun LG, Savaraj N, Wu C, You M, Wangpaichitr M, Marini A, Levi D, Bomalaski J, Kuo MT. Clinical and pharmacologic study of ADI-PEG20 in hepatocellular carcinoma. *Proc Am Soc Clin Oncol* 26: 661s, 2008
196. Bastos, BR, Wu C, Wangpaichitr M, Feun L, Robles C, Savaraj N. Overcoming cisplatin resistance with mTOR inhibition in small cell lung cancer- a phase I-II design. *Proc Am Soc Clin Oncol* 26: 641s, 2008
197. Feun LG, Wu C, You M, Kuo MT, Wangpaichitr M, Savaraj N. Possible mechanism of cell death in melanoma. *Proc AACR* 49: 233, 2008
198. Wangpaichitr M, Wu C, Kuo MT, You M, Feun L, Lampidis T, Savaraj N. Biochemical determinants for mTOR inhibitor sensitivity in lung cancer cell lines. *Proc AACR* 49: 277, 2008
199. Levi D, Moon J, Island E, Nishida S, Selvaggi G, Tekin A, Feun L, Garcia M, Bejarano P, Madrazo B, Arosemena L, O'Brien C, Martin P, Ruiz P, Schiff E, Tzakis A. Liver transplantation for hepatocellular carcinoma in the MELD era: Allocation Policy Implications. *Am Transplant Congress* May 2009
200. Savaraj N, Wu C, Wangpaichitr M, Feun LG. U-0126 potentiates arginine deprivation treatment in melanoma by inhibiting autophagy through inhibition of ERK. *Proc AACR* 50: 92, 2009
201. You M, Savaraj N, Wu C, Wangpaichitr M, Feun LG. Arginine deprivation and soluble TRAIL strikingly enhance death I argininosuccinate synthetase negative melanoma cells. *Proc AACR* 50: 825, 2009
202. C, Wangpaichitr M, Perez-Stable C, Feun LG, Savaraj N. Targeting androgen independent prostate cancer via nutritional and oxidative stress. *Proc AACR* 50: 1123, 2009.
1. 203 J. Wu, F. Muggia, C. Henderson, L. Feun, P. V. Veldhuizen, P. Gold, H. Zheng, G. Abbadessa, J. Lewis, A. X. Zhu. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. *Hepatobiliary Cancer* e15630 *J Clin Oncol* 27, 2009 (suppl; abstr e15630)
- 204 Feun LG, You M, Wu C, Wangpaichitr M, Kuo MT, Marini A, Jungbluth, Savaraj N. Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma. *Proc ASCO* vol 28:618s, 2010.
- 205 V. Dinh, M. You, N. Savaraj, C. Wu, M. T. Kuo, M. Wangpaichitr, L. G. Feun Determining argininosuccinate synthetase (ASS) expression in melanoma patients treated With arginine depleting therapy. *Proc ASCO* vol 29:661s, 2011

- 206 Wangpaichitr M, Wu C, You M, Feun LG, Kuo MT, Dinh Vy, Savaraj N. Downregulation of thioredoxin-1 confers resistance to cisplatin and sensitivity to the ROS generating agent Elesclomol. Proc AACR 52: 405,2011 Orlando, FL.
- 207 You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Feun L. TRAIL enhances cytotoxicity of arginine depletion therapy in argininosuccinate synthetase-negative melanoma cells through interruption of autophagy via activation of caspases. Proc AACR 52: 979, 2011 Orlando, FL.
- 208 Wen-Bin, T, Aiba I, Long Y, Lin H-K, Feun L, Savaraj N and Tien MT activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Proc AACR 53: , 2012
- 209 Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun LG, Kuo MT, Lampidis T and Savaraj N. The emerging role of thioredoxin-1 on ROS and metabolic re-programming in cisplatin resistant lung cancer. Proc AACR 53: 2012
- 210 Feun LG, Savaraj N, Narayanan G, Dinh V, O'Brien C, Rocha Lima C, Richman S, Schiff E, Martin P. Phase II trial of intrahepatic artery chemotherapy in combination with sorafenib in hepatocellular carcinoma patients. Proc ASCO vol 30: 2012
211. Medhi Wangpaichitr¹, George Theodoropoulos¹, Chunjing Wu¹, Nivit Poochareon¹, Ying Ying Li², Min You², Macus T. Kuo³, Lynn G. Feun², Niramol Savaraj¹. Selectively kill cisplatin resistant lung cancer cells by exploiting ROS and metabolic differences Proc AACR 54: 2013
- 212 Min You¹, Shu-Mei Chen², Chunjing Wu³, Ying-Ying Li¹, Lynn Feun¹, Medhi Wangpaithitr², Vy Dinh², Niramol Savaraj². Targeting procollagen secretory pathway for the treatment of primary brain tumor through ER stress. Proc AACR 54:2013
- 213 Lynn G. Feun¹, Govindarajan Narayanan¹, Jose Yrizarry¹, Vy Dinh¹, Niramol Savaraj², Christopher O'Brien¹, Paul Martin Pilot study of intrahepatic artery chemotherapy in combination with sorafenib in hepatocellular carcinoma patients. Proc AACR 54:2013
- 214 Max S. Rocha Lima, Lynn G. Feun, Peter Joel Hosein. Percutaneous irreversible electroporation (IRE) in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) to the liver: A retrospective analysis of the University of Miami experience. J Clin Oncol 30, 2012 (suppl 4; abstr 272)

(20) Other Works, Publications and Abstracts:

1. Feun LG: Intra-arterial Chemotherapy for Primary and Metastatic Brain Cancer. *Cancer Bulletin* 36:57-61, 1984.
2. Hwang TL and Feun LG: Primary Lymphoma of the Central Nervous System in a Homosexual Male. *Cancer Bulletin* 36:166-168, 1984.
3. Tang RA, Marroquin G, Feun LG, Prager T, Zarco I, and Garcia C: Ocular Toxicity and Intracarotid Infusion of Cisplatin. *Cancer Bulletin* 37:35-37, 1985.
4. Obbens EAMT and Feun LG: Treatment Options for Recurrent Brain Metastases. *Cancer Bulletin* 38:45-48, 1986.
5. Martinez-Prieto JH, Yung WKA, Feun LG, and Lee YY: Toxicity of Intracarotid Chemotherapy for Patients with Malignant Brain Tumors. *Cancer Bulletin* 38:49-53, 1986.
6. Feun LG: Review of Neurologic Oncology *J Natl Can Inst* July, 1988.
7. Feun LG: Symposium on Malignant Pleural Effusion. *Contemporary Surgery* 35:79-104, 1989.
8. Feun LG: Commentary. *Oncology* Oct 1989 p. 26-27.
9. Feun LG, Thurer R. "Tube Drainage and Intrapleural Therapy for Malignant Pleural Effusions: A Monograph: 1990
10. Feun LG, Savaraj N Letter to Editor. *J Florida Med Assoc Med Assoc* 78:840,1992.
11. Ardalan B, Shinwari J, Restrepo A, Deng Z-M, Livingstone A, Francheschi D, Sridhar K, Feun L, Sparling L. Phase I/II trial of high dose 24 hour infusion of Fluorodeoxyuridine in patients with colorectal cancer. (Submitted) 1
12. Mendel L, Feun LG. The role of intraperitoneal chemotherapy for ovarian malignancy. *Contemporary OB/GYN* 45:29-44,2000.
13. Feun L. *Oncology Times*. Vol XXIX No. 18, Sept 25, 2007
14. Feun L. *Oncology Times* Vol XXX No 2, Jan 25, 2008.
15. Feun L. *Oncology Times* Vol XXX No. 11, June 10, 2008

V. PROFESSIONAL

- (21) Funded Research Performed (include all grants received in the last five years, identifying the principal investigator):**

- A Phase I-II Study of Piritrexim (BW 30IU) Capsules in Advanced Melanoma. Burroughs Wellcome Co. One year (4/15/86-4/14/87) \$47,040.00: Principal Investigator, Lynn Feun, M.D.
- A Phase II Trial of Technetium, Labeled Monoclonal Antibodies in Patients with Melanoma. A. Serafini (Principal Investigator) L.G. Feun (Co-principal Investigator). (4/87- 3/88) \$40,000.00
- A Randomized Study Comparing Bleomycin with Tetracycline in Malignant Pleural Effusions, Bristol Laboratories. One year 9/1/86- 8/31/88) \$11,246.00: Principal Investigator, Lynn Feun, M.D.
- A Phase II Study of Piritrexim capsules in Advanced Melanoma. Burroughs Wellcome Co. (4/14/87-1/28/88) \$40,733.00.
- Intravenously administered. In-CYT-103 in the Imaging of Ovarian Carcinoma. PI: A Serafini Co PI: L.G. Feun. Cytogen (5/89-6/90) \$20,000.00.
- The clinical study of melanoma tumor detection comparing Indium labelled monoclonal antibody type 96S and Indium labelled ZME 018 in a cross- overstudy. A Serafini (Principal Investigator) L.G. Feun Co-Principal Investigator) Hybritech \$6,000.00 (1986-1987).
- Phase II Trial of Piritrexim in Combination with DTIC in Advanced Melanoma. Burroughs-Wellcome Co., Principal Investigator: Lynn Feun, M.D. (9/88-9/89) \$36,000.00.
- Clinical and Pharmacological Study of Intrahepatic Artery Infusion of Thiotepa, Phase I. Lederle Laboratories, Principal Investigator: Lynn Feun, M.D. (9/99-9/90) \$28,200.00
- A multicenter study to compare imaging of metastatic melanoma using technetium Tc99m labeled anti-melanoma monoclonal antibody with and without nonmelanoma antibody. A Serafini (Principal Investigator) L.G. Feun (Co-Principal Investigator) 2/90 - Present
- Antiemetic activity of different doses of methylprednisolone in combination with metoclopramide in cisplatin treated patients - Principal Investigator: Lynn Feun, M.D. (1-15-91 - 1-15-93) \$68,250.00
- Phase II trial of Piritrexim and Alkeran in advanced, previously treated bladder cancer. Burroughs-Wellcome (3-91 -3-93) - Principal Investigator: Lynn Feun, M.D. \$39,600.00
- Study of Marogen in chemotherapy-induced anemia - Upjohn Co. (1-91 - 2-92) Principal Investigator: Lynn Feun, M.D. \$37,500.00.

- A clinical trial of oral Navelbine for the treatment of women with advanced breast cancer (7-1-91 to 7-1-93) Burroughs-Wellcome Co. \$38,985.00. Principal Investigator: Lynn Feun, M.D.
- A clinical trial of intravenous Navelbine in first and second-line therapy of metastatic breast cancer (7-1-91 to 7-1-93) Burroughs-Wellcome Co. \$38,985.00. Principal Investigator: Lynn Feun, M.D.
- A trial of oral Navelbine for treatment of inoperable previously untreated stage IV non-small cell lung cancer (7-1-91 to 7-1-93) Burroughs-Wellcome Co. \$36,110.00. Principal Investigator: Lynn Feun, M.D.
- A randomized Phase III trial of melacine vs chemotherapy in patients with disseminated malignant melanoma R1B1 (9-3-91 to 9-3-93) Principal Investigator: Lynn Feun, M.D. \$24,999.00
- A phase II trial of recombinant alpha interferon (Intron) with BCNU, cisplatin, DTIC and Tamoxifen in advanced malignant melanoma.(1-10-92 to 1-9-94) Schering. Principal Investigator: Lynn Feun, M.D. \$15,000.00
- A Four-Arm Double-Blind Randomized Dose-Response Study of Oral Dolasetron Mesylate with IV Cyclophosphamide and/or Doxorubicin-Containing Chemotherapy, Merrill Dow 7/1/93 to 6/30/96. Principal Investigator: Lynn Feun, M.D. \$54,400.00
- A Four-Arm Double-Blind Randomized Study of Oral Dolasetron in Patients Receiving Carboplatin-Containing Chemotherapy 7/1/93 to 6/30/95. Principal Investigator: Lynn Feun, M.D. \$54,400.00
- Phase I Trial of 5-FUDR with Alpha-Interferon and Doxorubicin in Unresectable Hepatoma. Roche Lab. 10/93-10/94 \$20,000.00. PI: Lynn Feun, M.D.
- Phase II Trial of Taxol and DTIC in Advanced Malignant Melanoma (3194-3198) Principal Investigator: Lynn G.Feun, M.D.Amgen \$50,000.00 3/1/94-3/1/97
- Brain Tumor Research Center Grant: "New Therapeutic Approaches for Malignant Gliomas" (5/1/93 to 4/30/96). NIH \$225,000.00 I-P20-CA 60174-01 Program Project Director: Lynn Feun, M.D.
- Program Project "Immunity by Episome Transfer to Lung Tumors, Melanoma and CTL 9/30/92 - 9/29/96. \$3,901,000.00 Co-PI: Lynn Feun
- A Phase II Study to Evaluate Irinotecan Hcl (CPT-II) in Patients with Newly Diagnosed Inoperable Non-Small Cell Lung Cancer (NSCLC). Upjohn 12/1/94-11/30/97 \$87,000.00.

- Phase II Trial of Taxol and DTIC in Advanced Malignant Melanoma, Bristol Myers, \$15,000.00 (3/31/96 to 12/31/97)
- "Randomized Double-Blind, Placebo-Controlled, Phase II Study of RMP-7 in Combination with Carboplatin Administered Intravenously for the Treatment of Recurrent Malignant Glioma" Alkermes 10/1/95-10/17/97 \$33,000.00.
- Irinotecan (CPT-11): Phase II, Open-Label, Prospective Evaluation of Age as a Risk Factor for Development of Toxicities in Patients with 5-Fluorouracil Refractory Colorectal Cancer, Upjohn Company, 11/1/95-8/15/97 \$61,420.00.
- Phase III Trial of Melacine Plus Interferon Alpha-2-B vs. Interferon Alfa-2b in Patients with Disseminated Malignant Melanoma. RIBI, 11/15/96-1/14/98 \$37,000.00.
- Phase II Trial of Intravenous Navelbine + Tamoxifen in Advanced Melanoma. Glaxo-Wellcome. Principal Investigator. Lynn Feun, \$15,000.00 (7/1/96-7/1/97).
- Irinotecan Hydrochloride (CPT-1): Phase II Trial Using Every Other Week Dosing Schedule in Patients Previously Treated with 5-FU. Principal Investigator: Lynn Feun, Upjohn 9/1/96-8/31/98 \$33,000.00.
- An Open-Label Phase II Study to Evaluate a 28-Day Regimen of Oral-5-Fluorouracil (5-FU) Plus 776 C85 in Patients with Inoperable Hepatocellular Carcinoma. Glaxo-Wellcome 12/96-12/97. Principal Investigator: Lynn Feun, \$60,000.00
- A Pilot Study of the initiation of an autoimmune reaction to tumor in melanoma patients by cyclosporine A, alpha interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin and tamoxifen (Chiron) Principal Investigator: Lynn Feun, 1997-98
- Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Combined Immunotherapy with Subcutaneous Interleukin-2, and Histamine Dihydrochloride versus Subcutaneous Interleukin-2 Alone in Patients with Advanced Malignant Melanoma, Maxim Pharmaceuticals, \$30,600.00, 2/16/98-2/22/00.
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat in Patients with Glioblastoma, Multiforme or Gliosarcoma Following Completion of Conventional First-Line Treatment. British Biotech, 8/15/97-8/1/99.
- A Prospectively, Randomized, Double-Blind Comparative Multicenter Study to Evaluate Efficacy and Safety of Nyotran and Amphotericin-B for Empiric Antifungal Treatment in Neutropenic Patients. Aronex. \$32,000.00, End 5/31/98.
- An Open-Label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in

Cancer Patients Using A Single Intravenous Dose Schedule. Vion 3/16/98-7/31/99, \$60,000.00

- Phase II randomized dose study of subcutaneous administration of 3 different doses of pegylated interferon - α in patients with metastatic malignant melanoma. Hoffman LaRoche \$96,652. 9/14/00-3/31/02
- A randomized, double-blind trial comparing linezolid to vancomycin in the empiric treatment of febrile neutropenic oncology patients with suspected gram positive infections. Pharmacin J Upjohn 2001. \$90,000.
- A Phase III randomized controlled study comparing the survival of patients with unresectable hepatocellular carcinoma treated with thymitaq to patients treated with doxorubicin. Zarix 2001. \$50,000. 9/14/01-7/29/03.
- Phase I/II Study of T138067 Sodium in Patients with Advanced Surgically Unresectable Malignant Melanoma. Tularik 3/5/01-3/05/04 \$73,280.
- A Phase III, multi-center controlled trial with stratified randomization comparing the efficacy of interleukin 2 plus histamine dihydrochloride versus IL 2 alone to increase the duration of survival in patients with AJCC stage IV malignant melanoma with hepatic metastasis. Maxim. 7/12/02-6/30/07 \$258,888
- A Phase 2/3 open label, multicenter, randomized controlled study of doxorubicin hydrochloride adsorbed to magnetic targeted carriers (MTC-DOX) administered by intrahepatic delivery versus intravenous doxorubicin for treatment of patients with unresectable hepatocellular carcinoma. FedRx 9/10/02-9/05/04 \$164,481
- A Multi-center randomized, double-blind, placebo-controlled study of the safety and efficacy of dexmethylphenidate hydrochloride in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer subjects. Celgene 8/7/02-3/31/03 \$46,275
- A randomized study comparing MDX-010 alone or in combination with DTIC in the treatment of patients with chemotherapy naïve metastatic melanoma. Medarex 6/01/03-11/20/05 \$145,427
- A Phase 2/3 multicenter, randomized, controlled open-label study of intravenous T138067-sodium versus intravenous doxorubicin in subjects with chemotherapy-naïve, unresectable hepatocellular carcinoma. Tularik \$175,041. 3/5/01-3/4/04
- A Phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoma vaccine, CancerVax vaccine versus BCG plus a placebo as a post surgical treatment for stage III melanoma. CancerVax 8/12/03-8/1/08 \$225,813

- A Phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine CancerVax vaccine plus BCG versus placebo plus BCG as a Post-surgical treatment of stage IV melanoma. CancerVax 8/12/04-8/08 \$ 243,213
- A multicenter study to determine the safety of interleukin-2 plus histamine dihydrochloride for injection in subjects with AJCC stage IV malignant melanoma. Maxim 7/15/02 - 6/30/07 \$ 23,813.
- A Phase II, randomized open label study evaluating the antitumor activity of Medi-522, a humanized monoclonal antibody directed against the human alpha V beta 3 integrin +/- dacarbazine in patients with metastatic melanoma. MedImmune 10/3/03 - 10/2/08 \$39,314.
- R01 CA109578-01 NIH "Arginine Deprivation: A Targeted Therapy for Melanoma.7/04-7/07 PI: Lynn Feun \$204, 525.00
- Phase III trial of Taxoprexin injection vs dacarbazine in patients with metastatic malignant melanoma. Luitpol Pharm Inc 4/13/05-12/21/08 \$ 62,213
- A randomized, double-blind, multicenter study comparing MDX-010 monotherapy, MDX-010 in combination with a melanoma peptide vaccine, and melanoma vaccine monotherapy in HLA-A 0201-positive patients with previously treated unresectable stage III or IV melanoma. Medarex \$130, 158 6/13/05-4/24/09
- A randomized controlled study of Bay 43-9006 in combination with doxorubicin vs doxorubicin in patients with advanced hepatocellular carcinoma. Bayer. 6/10/05- 6/10/-9 \$41,808.
- A randomized 2-arm, open-label, phase II study of BMS-5822664 administered orally at a dose of 800 mg daily or doxorubicin administered intravenously at a dose of 60 mg/m² every 3 weeks in treating patients with unresectable, locally advanced or metastatic hepatocellular carcinoma. BMS4/10/-7-7/31/09 \$101,108.00.
- A phase I/II multi-center, blinded, randomized, controlled study of the safety and efficacy of the human monoclonal antibody to human alpha V beta 3 integrins (CTNO 95) alone and in combination with dacarbazine in subject with stage IV melanoma. Centocor 8/17/06-2/28/09 \$548,000.
- A multi-center randomized, double-blind, two-arm, phase III study in patients with untreated stage III (unresectable) or IV melanoma receiving dacarbazine plus 10 mg/kg of ipilimumab (MDX-010 vs. dacarbazine with placebo. BMS 3/8/07-3/8/011 \$112,075.
- A phase II trial of Zio-101 in advanced hepatocellular carcinoma Ziopharm 2/12/07-2/12/010 \$90,593.00

- Phase I pharmacokinetic/pharmacodynamic dose-finding and safety study of Trisenox (arsenic trioxide) injection in patients with hepatocellular carcinoma Cephalon 9/24/07-9/24/010 \$ 156,306.00
- Collection of long term outcome data for subjects who have previously participated in selected ipilimumab (MDX-010) studies in metastatic melanoma. Medarex 7/23/07-7/23/09 \$ 4,425.00.
- Phase II trial of Trisenox in Hepatocellular Carcinoma. Cephalon 6/13/07-6/30/09 \$156,305
- A Phase 2, open label, single arm, multicenter trial of the safety and antitumor effect of IPI-504, a novel heat shock protein, in patients with metastatic melanoma. Medimmune. \$ 75,911.00

A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. Bayer 7/21/08-7/21/12 \$86,350

A randomized, double-blind, phase 3 trial of STA-4783 in combination with paclitaxel alone for treatment of chemotherapy-naïve subjects with stage IV metastatic melanoma (Symmetry) 8/18/08- 8/18/12 \$106,003.

A multi-national, randomized, open-label, phase 3 study of sunitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Pfizer 11/28/08-11/29/12. \$26,081

A Phase II trial of intrahepatic artery chemotherapy with Nexavar in Hepatocellular carcinoma patients. Bayer 10/14/08-10/14/11 \$225,923 PI: Lynn Feun

A randomized phase 3 clinical trial to evaluate the efficacy and safety of treatment with OncoVEX compared to subcutaneously administered GM-CSF in previously treated melanoma patients with unresectable stage IIIb, IIIc and IV disease. 2/27/09 to 2/27/13 Biovex Inc. \$110,037.00

A double-blind randomized placebo-controlled phase III study to assess the efficacy of re MAGE-A3 + AS15 ASCL as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma. GlaxoSmithKline Biologicals 3/24/09- 4/24/14 \$ 106,204.

A phase II randomized, double blind, placebo controlled study of sorafenib or placebo in combination with transarterial chemoembolization performed with DC beads and doxorubicin for intermediate stage hepatocellular carcinoma. Bayer 7/09- 1/10 \$91,756.

A randomized, open label multicenter Phase II trial of the combination of bevacizumab plus erlotinib vs sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma. Genetech \$267,490.00 PI: Lynn Feun 9/09-9/10

Randomized, placebo-controlled, double blind phase III trial of sorafenib plus erlotinib vs sorafenib plus placebo as first line systemic therapy for hepatocellular carcinoma. Bayer 8/19/09- 8/18/13 PI: Lynn Feun \$74,947.00

Phase II trial of recombinant MAGE-A3 (recMAGE-A3) combined with AS15 immunological adjuvant system in advanced melanoma. GSK \$ 107,422 PI: Lynn Feun 12/23/09-1/25/16.

A randomized, open lable, controlled multicenter phase III study in previously untreated patients with unresectable stage IIIc or stage IV melanoma. Hoffman La Roche 4/26/10 to 6/30/12 \$ 559,483.

A double blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCL as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma. GSK 3/24/09- 4/24/14 Amendment. \$93,791 PI:Lynn Feun Phase 2, randomized study of CS-1008 in combination with sorafenib compared to sorafenib alone as first-line systemic therapy in subjects with advanced hepatocellular carcinoma. Daichli. 5/11/10 to 5/11/14 \$ 101,110. PI: Lynn Feun, MD

An open label, multicenter, phase III trial of ABI-007 vs Dacarbazine in previously untreated patients with metastatic malignant melanoma. \$ 307,072.50 PI: Lynn Feun Abraxis 6/09-6/13

“A prospective, multicenter, randomized, open-label, placebo-controlled, 2-parallel groups, phase 3 study to compare efficacy and safety of masitinib 7.5 mg/kg/day to dacarbazine in the treatment of patients with unresectable stage 3 or 4 melanoma carrying a mutation in the juxta membrane domain of c-kit,” AB Science \$42,556.00 PI: Lynn Feun

Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma 5R01CA152197-02 Sub-PI: Lynn Feun, MD 09/17/2010 – 07/31/2014 \$313,841/year x 4 years

Phase II trial of SOM230C (Pasireotide LAR) in patients with unresectable hepatocellular carcinoma (HCC) Novartis PI: Lynn Feun, March 2012 - April 2014 \$ 268,419.70

A prospective, single arm, multicenter, uncontrolled open label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant hepatocellular carcinoma Bayer PI: Lynn Feun, 11/ 2013 - \$ 244,536.00

(22) Editorial responsibilities:

Editorial Board: International Journal of General Medicine
Journal of Tumor
Reviewer for: Journal of Neuro-Oncology
Cancer Research
Cancer
Journal of the National Cancer Institute
Oncology
Cancer Investigation
Expert Review of Anticancer Therapy
Journal of Cellular and Molecular Medicine
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research (AACR)
Cell Death and Differentiation
Alimentary Pharmacology and Therapeutics
Clinical Insights: Oncology

(23) Professional and Honorary Organizations (member; officer;date):

- Fellow of the American College of Physicians
- Member of American Society of Clinical Oncology
- Member of American Association of Cancer Research
- Member of Southwest Oncology Group (SWOG) 1988-1992
- Gynecology Oncology Group
- Dade County Medical Association
- Florida Medical Association
- Member of Eastern Oncology Cooperative Group 1991- Present
- Collaborative Ocular Melanoma Study 1996 – Present
- Honorary member, Florida Society of Dermatologic Surgeons 2009

Study Section and Council Memberships

- NCI - Theradex Site Reviewer, University of Wisconsin, July 1984
- NCI Site Reviewer for Brain Tumor Cooperative Group, Silver Springs, MD,1986.
- NCI Site Reviewer, BTCG, Bethesda, MD, 1988.
- SWOG Brain Tumor Committee 1988 - 1992
- RTOG Brain Site Committee 1992 - Present
- ECOG Brain Tumor Working Group 1992-Present
- NCI Ad Hoc Special Review Committee December 1992.
- Sylvester Cancer Center Study Section 1997-98
- Sylvester Cancer Center- Clinical and Translational Research Committee 2000-Present
- Reviewer for Papanicolaou grant committee 2008

- Member of Working Group, NCI State of the Science Conference on HCC, December 12-13, 2008 . Washington DC.
- Reviewer for the British Lung Foundation 2012

American Cancer Society-Florida Division

- Peer Review Committee, December 1, 2000 – Tampa, FL
- American Cancer Society, Peer Review Committee, November 8, 2002 – Tampa. FL
- Ad hoc reviewer for Scottish Executive Health Department 2003.
- ACS Institutional Research Grant Review April 2007
- ACS Institutional Research Grant Reviewer 2012

(24) Honors and Awards:

1966	Phi beta Kappa
1966-1970	Student Aid Scholarship
1970	Graduated with High Distinction
6/1/87-5/31/88	Sylvester Foundation Clinical Investigator (Total \$40,748)
6/1/88-Present	The Best Doctors in America: Southeast Region (1996-7) The Best Doctors in America, 1998-9 The Best Doctors in America 2001-2002 “America’s Top Physicians” 2003, Consumers’ Research Council of America 1St Zubrod Award, University of Miami, June 2003 The Best Doctors in America 2003-2004 Best Doctors in America 2005-6 America’s Top Physicians 2006-Consumers’ Research Council of America AcademicKeys Who’s Who in Medical Sciences Education 2005- Best Doctors in America 2007-2008 Best Doctors in America 2009-2010 Best Doctors in America 2010-2014

(25) Post-Doctoral Fellowships:

(26) Other Professional Activities (e.g., papers presented; performance; conference proceedings; seminar or conference panel member; etc.):

1982	American Society of Clinical Oncology, St. Louis, MO.
1982	13th International Cancer Congress, Seattle, WA
1982	Third Southeast Asian & Western Pacific Regional Meeting Of Pharmacologists, Bangkok, Thailand

1982 Biochemical Modulators Advisory Group and Phase I Working Group, Bethesda, MD

1983 Fourth Asian-Oceanian Congress of Radiology, Bangkok, Thailand

1983 American Society of Clinical Oncology, San Diego, CA

1984 Mansell Bequest Symposium, Advances in Neuro-Oncology, London, England, October 22-23

1985 International Conference on Advances in Regional Cancer Therapy. Giessen, West Germany, August 26-28

1985 American Association of Cancer Research, Houston, TX

1986 American Association of Cancer Research, Los Angeles, CA

1987 NEORx Conference on Monoclonal Antibodies, Seattle, WA, Conference Panel Member.

1988 American Association of Cancer Research, New Orleans, LA

1988 American Society of Clinical Oncology, New Orleans, LA

1988 NeoRx Investigators Meeting, New Orleans, LA, Conference Panel Member.

1989 Current Status and Future Directions of Immunoconjugates, Monoclonal Antibody-based Imaging and Treatment, Orlando, FL, February 17-18, Conference Panel Member and Moderator.

1989 American Society of Clinical Oncology, San Francisco, May 21-24.

1989 American Association of Cancer Research, San Francisco, May 24-27.

1990 American Association of Cancer Research, Washington DC, May 23-26.

1994 American Association for Cancer Research, April 13, 1994, San Francisco, CA.

1995 American Association for Cancer Research, March 22, 1995. Toronto, Canada.

1996 Presentation and Panel Discussion. Current Status of Navelbine in Breast Cancer, Marco Island, Feb 1-2, 1996.

1996 American Association for Cancer Research, April 21, 1996, Washington, D.C.

1996 Presentation and Panel Discussion - Perspective in Melanoma, September 20-21, 1996, Pittsburgh, Penn.

1996 Presentation Society for Neuro-Oncology. First Scientific Meeting, Santa Fe, NM. Nov 8-10, 1996.

1997 American Association for Cancer Research April 12-16, 1997, San Diego, CA.

1997 Bristol Myers Investigators Meeting. Presentation, April 13, 1997, Atlanta, GA.

1997 Bristol Myers Investigator Meeting and Presentation April 1997, Dallas, TX.

1998 Joint Cancer Conference of the Florida Universities, Feb 26-28, 1998, Orlando, FL.

1998 American Association for Cancer Research, March 30, 1998

1999 Joint Cancer Conference of the Florida Universities, Jan 19, 1999, Orlando, FL

1999 American Association for Cancer Research, Philadelphia, PA, April 10-14, 1999.

1999 American Society of Clinical Oncology, Atlanta, Ga, May 15-18, 1999.

2000 American Association for Cancer Research, San Francisco, April 4, 2000.

2000 American Society of Clinical Oncology, New Orleans, May 22nd.

2001 American Association for Cancer Research, New Orleans, March 2001.

2001 American Society of Clinical Oncology, San Francisco, CA May 12.

2002 Joint Cancer Conference of the Florida Universities, Melanoma Panel and Lecturer Feb 1-2, 2002, Orlando

2002 Poster-Joint Cancer Conference of the Florida Universities, Feb. 1, 2002.

2002 American Association for Cancer Research, April 2002, San Francisco, CA

2002 American Society of Clinical Oncology, Orlando, May 2002

2003 Medical Center Grand Rounds, UM February 26, 2003

2003 Joint Cancer Conference of Florida University, February 20-21, 2003

2003 ASCO Chicago June 7, 2003

2003 Poster presentation, AACR

2004 ECOG protocol presentation, November 2003

2005 Poster presentation, ASCO. May 2005, Orlando, Fl.

Jan. 2005 Co-Chairman, Melanoma Update: Diagnosis and Treatment plus Presentations: Overview of IL2 programs at University Of Miami & Arginine Deprivation: a novel targeted therapy for melanoma Miami Beach, Fl

Jan 29, 2005 Lecture on Melanoma. Joint Cancer Conference, Orlando, FL.

April, 2005 Poster, American Association for Cancer Research, Anaheim, CA.

Oct. 2, 2005 Hepatoma Lecture, 9th Annual Fall Oncology Conference, Hilton Head, S.C.

2006 ASCO GI section. Poster on Phase III trial in hepatocellular carcinoma treated with Nolatrexed or doxorubicin

2006 American Association for Cancer Research, Washington, D.C.

2006 ASCO Poster on melanoma, Atlanta GA.

2006 Oral presentation and discussion, Ludwig Institute for Cancer Research, NY.

2007 AACR, poster presentation. LA, CA.

2007 Florida Cancer Conference, Palm Beach, Fl.

2008 Lecture: Hepatocellular Carcinoma in New Frontiers in Cardiovascular-Metabolic and Oncological Practices. International Medical Congress. Bangkok,Thailand.

2008 ADI Investigator Meeting at Ludwig Institute for Cancer Research, NY 3/28/08

2008 American Association for Cancer Research, Poster sessions San Diego, CA.

2009 Lecture to Florida Society of Dermatologic Surgeons, November 8,2009

2010 AACR poster. Washington D.C.

2010 ASCO poster, discussion, June 7, 2010 Chicago, Illinois

2011 Medicine Grand Rounds at Scott & White, Texas A & M, Temple, Tx 1/28/11

2011 AACR poster, Orlando , Fl.

2012 Lecture at Synergy Conference Miami Beach, Fl

2012 Invited Chair: the 7th Princess Chulabhorn International Science Congress on Cancer: From Basic Research to Cure, Bangkok, Thailand

2012 Invited speaker on: the 7th Princess Chulabhorn International Science Congress on Cancer: From Basic Research to Cure, Bangkok, Thailand

2013 AACR Poster presentation Washington DC

(27) Other professional activities:

May 1984 Lecture "Neuro-Oncology," Ohio State University

Jan. 1986 GOG Meeting, Anaheim, CA.

March 1986	Participated in Hybritech Conference on Monoclonal Antibodies for Melanoma, San Diego,CA. Conference Panel Member
May 1986	Lecture on "Principles of Chemotherapy." Review Course for Certification in Internal Medicine, Key Biscayne, FL
July 1986	Participant in Gynecologic Oncology Group Meeting, Winston-Salem, NC
Sep 1986	Standard SWOG Meeting, Columbus, OH.
Oct 1986	Participant in Symposium "Treatment of Infections in the Cancer Patient", Dallas, Texas.
Feb 28-	Attended SWOG Meeting, San Antonio, TX.
March 1987	Lecture on "Brain Tumors," Fort Lauderdale AMI Hospital, FL
April 1987	Symposium on 5FU, Detroit, MI.
May 1987	Lecture on "Principles of Chemotherapy." Review Course for Certification in Internal Medicine, Key Biscayne, FL.
July 1987	Attended Gynecologic Oncology Group Meeting, Las Vegas
August 1987	Lecture on "Principles of Chemotherapy" Review Course for Certification in Internal Medicine, Key Biscayne, FL.
1987	Lecturer, "Brain Tumors - Diagnosis and Treatment " AMI Hospital, Ft. Lauderdale, FL
Sept. 1987	Attended SWOG Meeting
Sept. 1987	Participant in seminar "Interferon as Adjunctive Therapy",Miami,FL
Dec. 1987	Monoclonal Antibody Workshop, Miami,FL
Feb. 1988	Attended Gynecologic Oncology Group Meeting, Miami,FL
April 1988	Attended SWOG Meeting, New Orleans,LA
Aug 1988 -	Investigator for Collaborative Ocular Melanoma Study.
Aug1988 -	Co-sponsor and participant in Bristol Myers Seminar, University of Miami, Miami,FL.
Oct 1988	Attended SWOG Meeting and Brain Tumor Committee Meeting, Seattle, WA
Oct 1988	Symposium on Malignant Pleural Effusion, American College of Surgeons and Contemporary Surgery, Seattle.WA
Oct 1988	Moderator for Cancer Center Network Program on Serious Infections
Nov 18, 1988	Speaker at Symposium on Cisplatinun Resistance in Human Tumors, Miami,FL "Pharmacokinetics of Cisplatin in Humans"
April 1989	Attended SWOG Meeting and Brain Tumor Committee Meeting, San Antonio, TX.
October, 1989	Attended SWOG Meeting and Brain Tumor Committee Meeting, Dearborn, Michigan, Oct. 13-14.
Feb 1-3, 1990	Attended GOG meeting, San Francisco, CA.
May 1-2, 1990	Attended Brain Tumor Committee, SWOG, Denver, Co.
Jul 20-21,1990	Attended GOG Meeting, New Orleans, LA
Oct 24, 1990	Attended SWOG Meeting, Columbus, Ohio, Presented data on TCN-P chemotherapy at Brain Tumor Committee.
Jan 10-12,1990	Chugai - Upjohn Investigators Meeting, Newport Beach, Ca.

Feb15-16,1991	Attended GOG Meeting, Orlando, FL.
Apr12-13, 1991	Attended SWOG Meeting and presented data, Phoenix,Az. Lecture "Melanoma" to Radiotherapy technologists.
May 16, 1991	AACR Poster Presentation In Vitro Antitumor Activity of U 73,975,in Multidrug and Cisplatin Resistant Cells, Houston, Tx.
May 17, 1991	AACR Poster Presentation Characteristics of Cisplatin - Resistant Human Small Cell Lung Cancer, Houston, Tx.
May 18, 1991	AACR Poster Presentation Compassionate Use of Oral Piritrexim in Advanced Bladder Cancer: An Effective Drug After Progression on MVACC Chemotherapy? Houston, Tx.
May 20, 1991	Panel discussion on brain tumors, ASCO, Houston, Tx.
Jul 20-21, 1991	Attended GOG Meeting, Indianapolis, Ind.
Aug 17-25, 1991	18th Annual Review Course for Certification in Internal Medicine "Fundamental and Clinical Aspects of Internal Medicine",Sheraton Brickell Point Hotel (Downtown)
Jan 31-Feb 1,1992	Attended GOG Meeting, Las Vegas
June 1992	Attended ECOG Brain Tumor Working Group Meeting, Baltimore
Jan 21, 1993	Presented lecture "Chemotherapy and Hormonal Therapy for Brain Metastases.First Miami Neuro-Oncology Symposium, Miami Beach, FL
Jan 21-23, 1993	Co-Director and also Moderator for First Miami Neuro-Oncology Symposium, Miami Beach, FL
Feb 10-12, 1993	Brain Tumor Core Committee, ECOG, Atlanta, GA
May 6-8, 1993	General Motors Symposium on Drug Resistance, Toronto, Canada
May 18, 1993	ECOG Brain Tumor Committee, Orlando, FL
May 20, 1993	Presented paper "Phase II Trial of Leukocyte Interferon plus Doxorubicin in Advanced Hepatoma. Proc Am Assoc Can Res, Orlando, FL.
Sept 28, 1993	Lecture "Brain Tumors", Oncology Grand Rounds, USC, CA
Oct 20-21, 1993	ECOG Meeting, Bal Harbour, FL.
Oct 23, 1993	Cancer Center Retreat, Islamorada, FL.
Oct 27, 1993	ECOG Site Visit, Tampa, FL.
Nov 11-14, 1993	Current Status of Navelbine in Non-Small Cell Lung Cancer, Dallas, TX.
Jan 27-28, 1994	Lecturer - Chemotherapy for Brain Tumors, Miami Neuro-Oncology Symposium, Key Biscayne. Moderator for Symposium.
Mar 20-21, 1994	Attended ECOG Meeting, Washington, D.C.
Apr 28-30, 1994	Navelbine Investigators Meeting, MacLean, Virginia
May 14-17, 1994	Attended ASCO Meeting, Dallas, TX.
Oct 5, 1994	Irinotecan Meeting (Upjohn),Kalamazoo,MI.
Feb 10, 1995	Dolasetron US Cancer Chemotherapy Investigator Meeting, Grapevine, TX.
Feb 23-25, 1995	Miami Neuro Oncology Symposium Co-Director, Moderator and Speaker, Miami, FL.
Apr 9, 1995	ECOG Meeting, Denver, Co.

Apr 21-22, 1995	Navelbine Investigators Forum, Tyson's Corner, Virginia
June 2-4, 1995	Visiting Faculty in Interferons, Annenberg Center, Palm Springs, CA.
Oct 13-14, 1995	ECOG Meeting, St. Louis, Mo.
Jan 18, 1996	Alkermes Investigator's Meeting, Tampa, FL
Oct 1, 1996	ECOG Meeting, Miami Beach, FL.
Nov 14-15, 1996	Glaxo Wellcome Investigator's Meeting, Houston, Texas.
Jan 29, 1997	ECOG Brain Tumor Core Committee, St. Louis.
March 20-22, 1997	Co-Director, Miami Neuro-Oncology Symposium, Miami Beach, FL.
April 18-19, 1997	ECOG Meeting, Atlanta, GA.
July 11-12, 1997	First International Proleukin Congress, San Francisco, CA
April 3-4, 1998	Bristol-Myers Squibb Clinical Research Investigators Meeting, Miami, FL.
May 1998	ASCO-Los Angeles, CA
June 1998	ECOG Meeting, Baltimore, MD
October 1998	Schering Melanoma Advisory Board, Atlanta, GA
November 1998	ECOG Meeting, Miami Beach, FL
February 26-28, 1999	Colorectal Cancer Faculty Work Shop, San Diego, CA
June 12-14, 1999	ECOG Brain Tumor Committee, Melanoma Committee, Baltimore, Maryland
August 27, 1999	Rhone-Poulenc Rorer Oncology Advisory Board Meeting, Dallas, TX
Jan 18-19, 2000	Investigators Meeting, Roche, Paris, France
May 4, 2000	Glaxo-Wellcome Protocol Meeting, Miami, FL
January 27, 2001	Issues on Prostate Cancer, Phoenix, AZ.
June 9, 2001	Tumor Advisory Board, Naples, Fl.
September 7-8, 2001	Consultant. Challenging cases in patient management, NY, NY.
April 11, 2002	EMD Pharmaceutical Investigator Meeting
June 5-7, 2003	ECOG Meeting New Orleans
June 2003	Judge for Posters at Zubord Awards Ceremony
November 2003	Perspectives in Melanoma Conference
November 2003	Eximias Investigator's meeting
April 19, 2004	CNTO 95 Phase I/II Melanoma Investigator Meeting, Los Angeles
April 23, 2004	Eximias Investigator Meeting, Miami, Fl.
July 15-16, 2004	3M Melanoma Advisory Board Meeting
October 7, 2004	Melanoma site disease group update, to Steering Committee
December 7, 2004	Presentation on Arginine deprivation for treatment of melanoma, Clinical Oncology Research Meeting
April 18- 20, 2005	Poster presentation, AACR, Anaheim, CA.
May 14-17, 2005	Poster presentation , ASCO, Orlando, Fl. May 16, 2005
September 14, 2005	Lecture "Novel treatments for Melanoma", Miami.
June 14, 2006	Poster discussion : Phase II study of ADI-PEG20 in melanoma.
June 25, 2006	Presented at ECOG melanoma meeting, Washington, D.C.

March 23, 2007	Grand Rounds for Radiation Oncology, Topic: Diagnosis and Treatment Hepatocellular Carcinoma
July 2007	Participant in Gordon Research Conference, New London, New Hampshire
October 2007	Participant in Nexavar Meeting
June 25-26, 2008	Bayer 12414 STORM Investigator Meeting, Barcelona, Spain.
November 2008	International Symposium on Cancer Therapeutics, Bangkok.
September 2012	Moderator: Modern Management of Resectable Melanoma, Miami
January 15, 2014	Grand Rounds for Dermatology: Past, Present and Back to the Future for Treatment of Malignant Melanoma

VI. TEACHING

(28) Teaching Awards Received:

(29) Current and past teaching responsibilities

Neurosurgery Conference Lecture:	October 18, 1985.
Neuro-Oncology Grand Rounds:	August 1, 1986.
Morbidity and Mortality Conference:	May 1, 1987.
VA Medical Student Attending:	May and June 1987
Conduct weekly Hematology/Oncology Housestaff-Fellow Meeting:	1986-1987
Teaching Attending (for Housestaff and medical students):	November 1985, February 1986, March 1986, December 1986, April 1987, October 1987, April 1988, September 1988
Oncology Emergencie-VA Housestaff	July 22, 1987
Oncology Emergencies - JMH Housestaff	July 28, 1987
Biology of Cancer Lecture to Undergraduates	September 22, 1987
Neurosurgery Grand Rounds	September 25, 1987
Biology of Cancer lecture to undergraduates	November 17, 1987
Morbidity and Mortality Conference:	December 11, 1987
Conduct Weekly Hematology/Oncology Housestaff-Fellow Conference CME Coordinator	1988-1989,
Medical Student Seminar Leader:	May 9, 1988
Oncologic Emergencies-VA Housestaff	August 2, 1988
Biology of Cancer lecture to undergraduates:	September 15, 1988
Grand Rounds - Dept. of Nuclear Medicine:	October 6, 1988.
Teaching Conference for Gynecology Oncology Fellows:	September 16, 1988.
Morbidity and Mortality Conferences, VA Hospital:	November 4, 1988.
Participates in Weekly Hematology/Oncology Journal Club	
Medical Residents Conference, VA Hospital:	December 9, 1988
Conduct weekly Hematology/Oncology Housestaff-Fellow Conference CME Coordinator	1988-1989

Mechanisms of Disease Course to Sophomore Medical Students:	March 6, 1989, March 10, 1989. March 20, 1989. March 27, 1989. April 3, 1989. April 17, 1989.
Conduct weekly Hematology/Oncology Housestaff-Fellow Conference CME Coordinator	1989-Present
Morbidity and Mortality Conference, JMH:	March 31, 1989.
Lecture "Brain tumors" to second year medical students:	April 25, 1989.
Lecture "Endocrine Cancers" to second year medical students:	May 2, 1989.
Lecture "Sarcomas: to second year medical students:	May 9, 1989.
Neurosurgical Grand Rounds, Brain Tumor Therapy:	April 14, 1989.
Teaching Attendings for Housestaff WW12:	September 1-30, 1989.
Medical Student Clinical-Pathological Seminar:	December 6, 1989.
Mechanisms of Disease Course to Sophomore Medical Students	January 1990-March 1990.
Lecture to sophomore medical students - "CNS Tumors":	April 14, 1990
Lecture to sophomore medical students - "Sarcomas"	April 19, 1990
Teaching Attending for Housestaff- WW12:	May 1-31, 1990
Postgraduate Lecture Series in Oncology, "Principles of Chemotherapy":	September 17, 1990
Neurosurgery Grand Rounds, "Advances in Chemotherapy for Brain Neoplasms", University of Miami:	September 21, 1990,
Lecture "Melanoma" to UM Housestaff, VA Hospital:	November 16, 1990.
Lecture "Pleural Effusions"-Hematology/Oncology Conf:	February 20, 1991.
Teaching Attending for Housestaff:	February 1-28, 1991.
Teaching Attending for Housestaff:	June, 1991.
Radiation Oncology Grand Rounds - "Malignant Melanoma"	November 4, 1991.
Mechanism of Disease Course - Sophomore Medical Students. "Paraneoplastic Syndrome."	January 30, 1991.
Mechanisms of Disease Course - Sophomore Medical Students "Principles of Chemotherapy":	January 30, 1991.
Lecture to GYO fellow and residents "Intrahepatic Artery Chemotherapy":	March 20, 1992.
Teaching Attending for Housestaff:	August 1-31, 1992.
Lecture to Housestaff, fellows, and attendings "Regional Therapy for Liver Metastasis":	October 16, 1992.
Grand Round Lectures in Nuclear Medicine, "Brain Tumors":	October 28, 1992.
Sophomore Clinical Skills Course:	November 1992-May 1993
Teaching Attending – UMHC:	March 1993
Hematology/Oncology Conference "Diagnosis and Management of CNS Tumors":	July 21, 1993
Teaching Attending for Housestaff:	September 1-30, 1993.
Lecture, "Current Update in Melanoma".	
Hematology/Oncology Conference:	September 22, 1993.
SCCC Oncology Grand Rounds "Hepatoma":	October 1, 1993.

Radiation Oncology Grand Rounds "Chemotherapy for Brain Tumors"	Oct. 28, 1993.
Gynecology Oncology Rounds: "Current Update on Malignant Melanoma":	November 19, 1993.
SCCC Oncology Grand Rounds: "Brain Tumors":	December 3, 1993.
Teaching Attending for Housestaff, UMHC:	December, 1993.
Sophomore Clinical Skills Course:	November, 1993-May, 1994.
Lecture "Brain Tumors" Hematology/Oncology Fellows Conference:	Oct. 12, 1994.
Lecture "Chemotherapy of Brain Tumors"	Dec. 22, 1994.
Radiation Oncology Grand Rounds:	August -December 1994.
Sophomore Clinical Skills Course:	April 12, 1995.
Lecture - Brain Tumors - Nuclear Medicine Grand Rounds:	
Neurosurgery Resident Conference	
"Chemotherapy in Brain Tumors":	July 26, 1995.
Teaching Attending for Housestaff, JMH:	September 1995.
Sophomore Clinical Skills Course:	August 1995 - May 1996.
Hematology/Oncology Conference Brain Tumor:	December 20, 1995.
Grand Medical Rounds "Melanoma-Update":	January 31, 1996.
Hematology/Oncology Conference	
Melanoma-Risk Factors, Etiology and Incidence:	October 2, 1996.
Radiation Oncology Grand Rounds, "Chemotherapy for Brain Tumors":	November 21, 1996.
Teaching Attending for Housestaff:	February 1-28, 1997.
Hematology-Oncology Conference	
"Treatment of Hepatocellular Carcinoma":	September 30, 1998.
Hematology-Oncology Fellow Conference.	
Malignant Melanoma:	Sept. 16, 1999.
Clinical Research Skills, Sophomore Medical Students:	July 1998
Clinical Research Skills, Sophomore Medical Students:	1999-2000
Lecture to Mt. Sinai Medical Center House Staff Hepatoma:	Jan 5,2000.
Lecture to Dermatology Seminar Univ.of Miami	September 6, 2000
Lecture to Radiation Oncology Grand Rounds Univ.of Miami	September 27,2000
Lecture Hem/Onc Fellow, Melanoma:	Feb. 15, 2001.
Clinical Research Skills, Sophomore Medical Students:	2000-2001.
Management of Hepatocellular Carcinoma. Hem-Onc Conference:	Sept. 19, 2001.
Lecture Radiation Oncology Grand Round, Hepatoma:	December 14, 2001.
Clinical Research Skills, Mentor for Sophomore Medical Students:	2002-2003
Clinical Research Skills, Mentor for Sophomore Medical Students:	2004-2005
Lecture to JMH residents conference, Hepatoma:	November 16, 2004
Lecture Oncology fellow, Therapy for Hepatoma:	December 13, 2005
Clinical Research Skills, Mentor for Sophomore Medical Students	2006-2007
Lecture to hem/onc fellow conference. Hepatocellular carcinoma:	January 18, 2007
Lecture to hem/onc fellow conference. Malignant melanoma	September 25, 2007
Lecture to Biology students, Diagnosis and therapy for melanoma	December 10, 2007
Lecture to UM residents at JMH, Hepatoma-Dx and Therapy	December 17,2007

Lecture to UM Cancer Biology Ph D students	December 8, 2008
Clinical Research Skills, Mentor for Sophomore Medical Students	2008-2009
Lecture to UM Hem/Onc fellows-Hepatocellular carcinoma	January 20,2009
Lecture Hematology/Oncology Conference-Amino acid deprivation :a targeted therapy for cancer	February 4, 2009
Lecture to Hem/Onc fellows-therapy for melanoma	June 11,2009
Lecture to Hepatology fellows-chemotherapy for HCC	June 22, 2009
Clinical Research Skills, Mentor for Sophomore Medical Students	2009-2010
Lecture to Hepatology fellows-Treatment for HCC	March 22,2010
Clinical Research Skills, Mentor for Sophomore Medical Students	2010-2011
Lecture to Hem/Oncology Fellows on Hepatoma	April 12, 2011
Lecture to Hem/Oncology Fellows on Melanoma	September 20, 2011
Clinical Research Skills, Mentor for Sophomore Medical Students	2011- 2012
Associate Member (founding member) Academy of Medical Educators at the University of Miami	Feb 7, 2012
Lecture to Hem/Onc fellows-Hepatocellular carcinoma	Feb 21, 2012
Lecture to Hem/Onc fellow-Liver cancer	Sept 18, 2012
Core Lecture to Hem/Onc fellows-Melanoma uptake	Nov 13, 2012
Clinical Research Skills, Mentor for Sophomore Medical Students	2012-2013
Hematology/Oncology Grand Rounds-Melanoma	August 14, 2013
Lecture to Hem/Oncology Fellows on Hepatocellular carcinoma	January 20,2014
(30) Thesis and Dissertation Advising/Post-doctoral student supervision (chairman or committee member; topic; student name; date):	

VII. SERVICE

(31) University Committee and Administrative Responsibilities:

1989-1992	Medical Library Committee.
1989-1990	Cancer Center Core Curriculum Committee.
1989-Present	Head, Melanoma Working Group.
1990-1991	Search Committee for Department of Oncology Chairmanship
1990-Present	Clinical Research Committee, Sylvester Cancer Center
1991-Present	Protocol Review Committee Meeting, Sylvester Cancer Center
1991	Scientific and Clinical Affairs Committee
1992	Rehabilitation Center Meeting.
1991-Present	Scientific and Clinical Advisory Board. Brain Endowment Bank
1993 – 2001	Cancer Control Committee
1997 – 1999	Medical Library Committee-
1999 – 2001	Promotion and Tenure Committee
1999- 2002	Protocol Review Committee Sylvester Cancer Center-
2001 - 2012	Chairman, Pharmacy and Therapeutic Committee, Sylvester Cancer Center.
2001	Clinical Research Services Users Committee
2001	UMHC/Sylvester Executive Committee

2008 UM Hospital Cancer Committee

(32) Community Activities:

May 1, 1991 Lecture "What's New in Chemotherapy-Immunotherapy in Melanoma". Broward County and Dermatology Society.

Oct 9, 1991 Lecture "Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions" Tumor Board, University Hospital in Tamarac, FL.

July 28, 1993 Lecture "Diagnosis and Management of Malignant Pleural Effusions" North Shore Hospital Tumor Board

August 6, 1993 Lecture "Malignant Pleural Effusions, Tumor Board, Mercy Hospital, Miami, FL.

July 15, 1998 Boca Raton Community Hospital Oncology Conference

May 5, 2003 Melanoma Monday Skin Awareness with Melanoma Foundation, Boca Raton, FL

May 23, 2003 Lecture, Building Hope Through Knowledge Conference for Brain Tumor Patients, Miami, FL.

August 22, 2003 Lecture Melanoma Treatment, in Towne Meeting on Skin Cancer, JMH

May 22, 2004 Lecture on New Agents for Malignant Gliomas in the Florida Brain Tumor Association meeting, Fort Lauderdale

June 25, 2004 Lecture, Melanoma-Diagnosis and Treatment, Deerfield Beach

Sept. 18, 2004 Lecture for Melanoma Foundation, Boca Raton

February 18, 2005 Lecture, Deerfield Beach community.

April 2, 2005 Lecture to National Cancer Survivors, Pembroke Pines
" Smart Bombs in the War against Cancer"

May 26, 2005 Lecture to community at Wellness Center, Miami

Nov 15, 2005 Lecture to Greater Boynton Beach unit of Pap Women Corp

Feb 24, 2006 Lecture at Deerfield Beach on Hepatoma

March 10, 2007 Lecture at the Melanoma Foundation, West Palm Beach, FL.

June 20, 2005 Telemedicine lecture to Brazil oncologists on Hepatoma.

June 11, 2008 Lecture and Discussion on Melanoma, Wellness Community

September 10-11 Lecture to Cayman Cancer Society and lectures to community

(33) Consultantships:

1986-1987 Physician Advisory Board to Oncology Program at AMI Hospital, Tampa, FL.

1995 Schering Melanoma Advisory Board, Jacksonville, FL.

1996 Schering National Melanoma Faculty

2004 3M Melanoma Advisory Board